<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002209" GROUP_ID="ADDICTN" ID="828299072215335943" MERGED_FROM="" MODIFIED="2009-05-05 09:18:31 +0200" MODIFIED_BY="Laura Amato" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-04-07 10:33:11 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="9" REVMAN_SUB_VERSION="5.0.18" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2009-05-05 09:18:31 +0200" MODIFIED_BY="Laura Amato">
<TITLE>Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence</TITLE>
<CONTACT MODIFIED="2009-05-05 09:18:31 +0200" MODIFIED_BY="Laura Amato"><PERSON ID="F161FFCE82E26AA201CB1278D729D933" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Mattick</LAST_NAME><POSITION>Director of Research</POSITION><EMAIL_1>R.Mattick@unsw.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>National Drug and Alcohol Research Centre</DEPARTMENT><ORGANISATION>University of New South Wales</ORGANISATION><ADDRESS_1>National Drug and Alcohol Research Centre</ADDRESS_1><ADDRESS_2>University of New South Wales</ADDRESS_2><CITY>Sydney</CITY><ZIP>2052</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 (0) 2 9385 0333</PHONE_1><FAX_1>+61 (0) 2 9385 0222</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-05-05 09:18:31 +0200" MODIFIED_BY="Laura Amato"><PERSON ID="F161FFCE82E26AA201CB1278D729D933" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Mattick</LAST_NAME><POSITION>Director of Research</POSITION><EMAIL_1>R.Mattick@unsw.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>National Drug and Alcohol Research Centre</DEPARTMENT><ORGANISATION>University of New South Wales</ORGANISATION><ADDRESS_1>National Drug and Alcohol Research Centre</ADDRESS_1><ADDRESS_2>University of New South Wales</ADDRESS_2><CITY>Sydney</CITY><ZIP>2052</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 (0) 2 9385 0333</PHONE_1><FAX_1>+61 (0) 2 9385 0222</FAX_1></ADDRESS></PERSON><PERSON ID="13338" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Courtney</FIRST_NAME><LAST_NAME>Breen</LAST_NAME><POSITION>Senior research officer</POSITION><EMAIL_1>courtney.breen@unsw.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>National Drug and Alcohol Research Centre</DEPARTMENT><ORGANISATION>University of New South Wales</ORGANISATION><ADDRESS_1>National Drug and Alcohol research Centre</ADDRESS_1><ADDRESS_2>University of New South Wales</ADDRESS_2><CITY>Sydney</CITY><ZIP>2052</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61-2-93850282</PHONE_1><FAX_1>61-2-93850222</FAX_1></ADDRESS></PERSON><PERSON ID="13355" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jo</FIRST_NAME><LAST_NAME>Kimber</LAST_NAME><POSITION>Research Fellow</POSITION><ADDRESS><DEPARTMENT>Centre for Research on Drugs and Health Behaviour</DEPARTMENT><ORGANISATION>London School of Hygiene and Tropical Medicine</ORGANISATION><ADDRESS_1>Keppel Street</ADDRESS_1><CITY>London</CITY><ZIP>WC1E 7HT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>020 7958 8158</PHONE_1></ADDRESS></PERSON><PERSON ID="6213" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Marina</FIRST_NAME><LAST_NAME>Davoli</LAST_NAME><POSITION>Coordinating Editor</POSITION><EMAIL_1>davoli@asplazio.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>ASL RM/E</ORGANISATION><ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1><CITY>Rome</CITY><ZIP>00199</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 06 83060 483</PHONE_1><FAX_1>+39 06 83060463</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-03-05 15:52:23 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 13/02/03&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-03-05 15:52:23 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="19" MONTH="2" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="12" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="2" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2009-03-05 10:10:39 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2009-03-05 10:10:39 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>new trials included, analysis changed in respect to the previous version, quality assessment changed following the new rules of the Collaboration</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-03-05 09:41:26 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>new search, new studies found</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-02-10 04:03:35 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2009-02-10 04:03:35 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="2" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>National Drug and Alcohol Research Centre, University of New South Wales, Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Commonwealth Department of Health and Aged Care, Canberra</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-03-16 09:10:38 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-03-05 10:14:10 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-03-05 10:14:10 +0100" MODIFIED_BY="[Empty name]">Methadone maintenance therapy versus no opioid replacement therapy</TITLE>
<SUMMARY_BODY MODIFIED="2009-01-26 22:09:21 +0100" MODIFIED_BY="[Empty name]">
<P>Methadone maintenance treatment can keep people who are dependent on heroin in treatment programs and reduce their use of heroin. Methadone is the most widely used replacement for heroin in medically-supported maintenance or detoxification programs. Several non-drug detoxification and rehabilitation methods are also used to try and help people withdraw from heroin. However the review found that people have withdrawn from trials when they are assigned to a drug-free program. Consequently, there are no trials comparing methadone maintenance treatment with drug-free methods other than methadone placebo trials, or comparing methadone maintenance with methadone for detoxification only. These trials show that methadone can reduce the use of heroin in dependent people, and keep them in treatment programs.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-03-05 15:04:20 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-03-05 15:02:50 +0100" MODIFIED_BY="[Empty name]">
<P>Methadone maintenance was the first widely used opioid replacement therapy to treat heroin dependence, and it remains the best-researched treatment for this problem. Despite the widespread use of methadone in maintenance treatment for opioid dependence in many countries, it is a controversial treatment whose effectiveness has been disputed.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effects of methadone maintenance treatment (MMT) compared with treatments that did not involve opioid replacement therapy (i.e., detoxification, offer of drug-free rehabilitation, placebo medication, wait-list controls) for opioid dependence. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-03-05 15:04:20 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following databases up to Dec 2008: the Cochrane Controlled Trials Register, EMBASE, PubMED, CINAHL, Current Contents, Psychlit, CORK [www. state.vt.su/adap/cork], Alcohol and Drug Council of Australia (ADCA) [www.adca.org.au], Australian Drug Foundation (ADF-VIC) [www.adf.org.au], Centre for Education and Information on Drugs and Alcohol (CEIDA) [www.ceida.net.au], Australian Bibliographic Network (ABN), and Library of Congress databases, available NIDA monographs and the College on Problems of Drug Dependence Inc. proceedings, the reference lists of all identified studies and published reviews; authors of identified RCTs were asked about other published or unpublished relevant RCTs.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised controlled clinical trials of methadone maintenance therapy compared with either placebo maintenance or other non-pharmacological therapy for the treatment of opioid dependence.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-01-27 04:59:03 +0100" MODIFIED_BY="[Empty name]">
<P>Reviewers evaluated the papers separately and independently, rating methodological quality of sequence generation, concealment of allocation and bias. Data were extracted independently for meta-analysis and double-entered.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-01-27 04:18:55 +0100" MODIFIED_BY="[Empty name]">
<P>Eleven studies met the criteria for inclusion in this review, all were randomised clinical trials, two were double-blind. There were a total number of 1969 participants. The sequence generation was inadequate in one study, adequate in five studies and unclear in the remaining studies. The allocation of concealment was adequate in three studies and unclear in the remaining studies. Methadone appeared statistically significantly more effective than non-pharmacological approaches in retaining patients in treatment and in the suppression of heroin use as measured by self report and urine/hair analysis (6 RCTs, RR = 0.66 95% CI 0.56-0.78), but not statistically different in criminal activity (3 RCTs, RR=0.39; 95%CI: 0.12-1.25) or mortality (4 RCTs, RR=0.48; 95%CI: 0.10-2.39).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-01-12 00:17:01 +0100" MODIFIED_BY="[Empty name]">
<P>Methadone is an effective maintenance therapy intervention for the treatment of heroin dependence as it retains patients in treatment and decreases heroin use better than treatments that do not utilise opioid replacement therapy. It does not show a statistically significant superior effect on criminal activity or mortality.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-03-16 09:10:38 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-03-05 10:32:15 +0100" MODIFIED_BY="[Empty name]">
<INTERVENTION MODIFIED="2009-03-05 10:31:27 +0100" MODIFIED_BY="[Empty name]">
<P>Currently, the major form of medical therapy for heroin dependence internationally involves orally administered methadone. Methadone is an analgesic medication developed to treat pain in the 1940s. It has been, and is still, prescribed widely for the management of pain in America, Australia and Europe.</P>
<P>It was in New York in the 1960s, during an increase in heroin use and heroin dependence, that researchers (<LINK REF="REF-Dole-1965" TYPE="REFERENCE">Dole 1965</LINK>; <LINK REF="REF-Dole-Nyswander-1967" TYPE="REFERENCE">Dole Nyswander 1967</LINK>) examined different prescribed opioids to manage heroin dependence, and reported that they found that methadone was most suitable to the task. They believed that long-term heroin use caused a permanent metabolic deficiency in the central nervous system and an associated physiological disease, which required regular administration of opiates to correct the metabolic deficiency (<LINK REF="REF-Dole-Nyswander-1967" TYPE="REFERENCE">Dole Nyswander 1967</LINK>). The disorder of opioid dependence has been represented in the International Classification of Disease of the World Health Organisation. It is a chronic or long-term and relapsing disorder, and some believe that it requires ongoing maintenance medication.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-03-05 10:31:52 +0100" MODIFIED_BY="[Empty name]">
<P>The aspects of methadone that have led to its use as a substitute drug for heroin include the number of pharmacological features of opioids. At the basis of methadone maintenance treatment (MMT) is the observation that opioid analgesics can be substituted for one another (<LINK REF="REF-Jaffe-1990" TYPE="REFERENCE">Jaffe 1990</LINK>). Methadone at adequate doses (of 20mg to more than 100 mg) prevents or reverses withdrawal symptoms (<LINK REF="REF-Ward-1992" TYPE="REFERENCE">Ward 1992</LINK>), and thus reduces the need to use illegal heroin (<LINK REF="REF-Jaffe-1990" TYPE="REFERENCE">Jaffe 1990</LINK>). Methadone remains effective for approximately 24 hours, requiring a single daily dose rather than the more frequent administration of three to four times daily which occurs with the shorter-acting heroin (<LINK REF="REF-Jaffe-1990" TYPE="REFERENCE">Jaffe 1990</LINK>). Methadone can "block" the euphoric effects of heroin, discouraging illicit use and thereby relieving the user of the need or desire to seek heroin (<LINK REF="STD-Dole-1969" TYPE="STUDY">Dole 1969</LINK>). This allows the opportunity to engage in normative activities, and "rehabilitation" if necessary. Methadone can cause death in overdosage, like other similar medications such as morphine, and for this reason it is a treatment which is dispensed under medical supervision and relatively strict rules. In summary, methadone is a long-acting opioid analgesic with well-understood pharmacological characteristics which make it suitable for stabilising opioid dependent patients in a maintenance treatment approach.</P>
<P>There is evidence that the quality of the therapeutic relationship with staff in methadone clinics plus the intensity of these ancillary services, combined with the dose of methadone prescribed will all act to enhance the outcome for methadone treatment (<LINK REF="REF-Ward-1992" TYPE="REFERENCE">Ward 1992</LINK>), although this is not the focus of this review.</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-03-05 10:32:03 +0100" MODIFIED_BY="[Empty name]">
<P>Methadone maintenance treatment remains one of the best researched treatments for opioid dependence (<LINK REF="REF-Cooper-1983" TYPE="REFERENCE">Cooper 1983</LINK>; <LINK REF="REF-Gerstein-1990" TYPE="REFERENCE">Gerstein 1990</LINK>; <LINK REF="REF-Hargreaves-1983" TYPE="REFERENCE">Hargreaves 1983</LINK>; <LINK REF="REF-Mattick-1993" TYPE="REFERENCE">Mattick 1993</LINK>; <LINK REF="REF-Ward-1992" TYPE="REFERENCE">Ward 1992</LINK>). It is the only treatment for opioid dependence which has been clearly demonstrated to reduce illicit opiate use more than either no-treatment (<LINK REF="STD-Dole-1969" TYPE="STUDY">Dole 1969</LINK>; <LINK REF="STD-Yancovitz-1991" TYPE="STUDY">Yancovitz 1991</LINK>; <LINK REF="STD-Dolan-2003" TYPE="STUDY">Dolan 2003</LINK>; <LINK REF="STD-Schwartz-2006" TYPE="STUDY">Schwartz 2006</LINK>, <LINK REF="STD-Kinlock-2007" TYPE="STUDY">Kinlock 2007</LINK>), drug-free treatment (<LINK REF="STD-Gunne-1981" TYPE="STUDY">Gunne 1981</LINK>), placebo medication (<LINK REF="STD-Newman-1979" TYPE="STUDY">Newman 1979</LINK>; <LINK REF="STD-Strain-1993a" TYPE="STUDY">Strain 1993a</LINK>), or detoxification (<LINK REF="STD-Vanichseni-1991" TYPE="STUDY">Vanichseni 1991</LINK>; <LINK REF="STD-Gruber-2008" TYPE="STUDY">Gruber 2008</LINK>; <LINK REF="STD-Sees-2000" TYPE="STUDY">Sees 2000</LINK>) in clinical controlled trials. These trials have been conducted by different research groups, in markedly differing cultural settings, yet have converged to provide similar results.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>The present systematic review aimed to provide an evaluation of the effectiveness of methadone maintenance treatment on opioid dependence compared with treatments that did not include an opioid replacement therapy. The focus of the review is on retention in treatment, opioid use as measured by objective urine results and from self-report, as well as criminal activity and patient mortality.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-03-05 14:34:12 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-03-05 10:37:46 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>The literature was reviewed for all clinical controlled trials of MMT against another treatment which does not use opioid replacement therapy. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Individuals who were opioid dependent were the target population for this review. No distinction was made between those using heroin and those who have been in methadone treatment prior to entering the research trial treatment. No restrictions were imposed in terms of studies of outpatients, inpatients, those with comorbid states, etc.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Interventions were included if they used methadone maintenance therapy (MMT). The MMT interventions were included even where they also employed other treatments, such as behavioural therapies or outpatient rehabilitation. The control groups were treated with placebo medication, withdrawal or detoxification (with or without ancillary medication), drug-free rehabilitation treatment (such as therapeutic communities), and no treatment or wait-list controls. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-03-05 10:37:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-03-05 10:37:19 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>retention in treatment</LI>
<LI>mortality</LI>
<LI>proportion of urine or hair analysis results positive for heroin (or morphine)</LI>
<LI>self-reported heroin use</LI>
<LI>criminal activity</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-03-05 10:37:40 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>use of other drugs</LI>
<LI>physical health</LI>
<LI>psychological health</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-03-05 10:53:57 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2009-03-05 10:53:57 +0100" MODIFIED_BY="[Empty name]">
<P>1.Cochrane Central Register of Controlled Trials, which includes the Cochrane Drugs and Alcohol Group Register of Trials (CENTRAL - The Cochrane Library issue 4, 2008)<BR/>2.PubMed (January 2001 - December 2008)<BR/>3.Embase (January 2001- December 2008)<BR/>4.CINAHL (January 2001 - December 2008)</P>
<P>For details on searches see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>
</P>
<P>The search strategy was developed in consultation with a drug and alcohol research information specialist.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-03-05 10:44:52 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Some of the main electronic sources of ongoing trials (National Research Register, meta-Register of Controlled Trials; Clinical Trials.gov, Agenzia Italiana del Farmaco)</LI>
<LI>Conference proceedings likely to contain trials relevant to the review (College on Problems of Drug Dependence - CPDD)</LI>
<LI>Library of Congress databases were also searched for studies and book chapters with the key terms: methadone, clinical trial, and randomised control trial.</LI>
<LI>National focal points for drug research (e.g., National Institute of Drug Abuse (NIDA), National Drug &amp; Alcohol Research Centre (NDARC))</LI>
<LI>Reference lists of all relevant papers to identify further studies.</LI>
<LI>Authors of identified RCT's were consulted to find out if there were any other published or unpublished RCT's comparing the efficacy of methadone maintenance vs against another treatment which does not use opioid replacement therapy.</LI>
<LI>As several drug and alcohol journals are not indexed on the main electronic databases, the following databases were searched up until December 2008:</LI>
</OL>
<UL>
<LI>"Current Contents</LI>
<LI>"Psychlit</LI>
<LI>"CORK [www. state.vt.su/adap/cork]</LI>
<LI>"Alcohol and Drug Council of Australia (ADCA) [www.adca.org.au]</LI>
<LI>"Australian Drug Foundation (ADF -VIC) [www.adf.org.au]</LI>
<LI>"Centre for Education and Information on Drugs and Alcohol (CEIDA) [www.ceida.net.au]</LI>
<LI>"Australian Bibliographic Network (ABN).</LI>
</UL>
<P>All searches included non-English language literature and studies with English abstracts were assessed for inclusion. When<BR/>considered likely to meet inclusion criteria, studies were translated.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-03-05 14:34:12 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-03-05 10:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>Each potentially relevant study located in the search was obtained and independently assessed for inclusion by two of three reviewers. Data extraction for each study was undertaken by the same two reviewers, again independently.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-03-05 14:32:59 +0100" MODIFIED_BY="[Empty name]">
<P>Each potentially relevant study located in the search was obtained and independently assessed for inclusion by two of three reviewers. Data extraction for each study was undertaken by the same two reviewers, again independently. A standardised checklist was used for data extraction. Disagreement was dealt with by the third reviewer, acting as a mediator. If unresolved disagreements on inclusion, study quality or extraction occurred they were referred to the editor.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-03-05 14:33:19 +0100" MODIFIED_BY="[Empty name]">
<P>Due the type of comparisons analysed (MMT versus methadone detoxification or waiting list), blinding is often difficult to apply. As such, methodological quality was assessed by assessment of the randomisation procedure and the likelihood that randomisation was not biased:<BR/>A. Low risk of bias (allocation clearly independent of clinical staff);<BR/>B. Moderate risk of bias (some doubt about the independence of the allocation procedure); and<BR/>C. High risk of bias (inadequate separation of randomisation from clinical staff).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-03-05 14:33:36 +0100" MODIFIED_BY="[Empty name]">
<P>A standardised effect size was calculated for each study, based on the main outcome measure reported. Where possible (relative risks and 95% confidence intervals for dichotomous outcomes (retention) using a random effects model and standardised mean differences for continuous outcomes were presented. To assess for statistical heterogeneity a test of homogeneity was undertaken. A pooled effect size estimate was derived for each domain of measurement (retention in treatment, urine analysis results for heroin/morphine ), self-reported heroin use, and criminal activity. The retention in treatment and urine results were reported as the number of patients retained or the number with a morphine-positive urine result at follow-up, a form of reporting that allowed for dichotomous analysis of those data.</P>
</EFFECT_MEASURES>
<DATA_SYNTHESIS MODIFIED="2009-03-05 14:34:10 +0100" MODIFIED_BY="[Empty name]">
<P>The results were integrated from the meta-analytic review into a discussion taking into consideration other publications including large-scale observational studies, studies of the pharmacology of methadone, and studies of the effect of MMT on HIV seroconversion. Convergence of the evidence from the meta-analysis and the narrative review was taken to indicate a robust conclusion.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-03-16 09:10:38 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-03-16 09:10:38 +0100" MODIFIED_BY="[Empty name]">
<P>We considered fourteen studies for inclusion, three were excluded because they did not satisfy the inclusion criteria (<I>see </I>
<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table) and eleven were included (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> Charachteristics table) with a total of 1969 participants.</P>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-03-09 23:09:46 +0100" MODIFIED_BY="[Empty name]">
<P>Eleven studies were included in this review. Refer to <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> Table for more detailed information.</P>
<SUBSECTION>
<HEADING LEVEL="4">Treatment regimes and settings</HEADING>
<P>The first study by Dole (<LINK REF="STD-Dole-1969" TYPE="STUDY">Dole 1969</LINK>) was a two group randomised trial where patients either received methadone or placed on a wait- list. The study by Gunne (<LINK REF="STD-Gunne-1981" TYPE="STUDY">Gunne 1981</LINK>) randomly allocated patients to receive methadone maintenance or to be allocated to a drug-free rehabilitation. None of the patients allocated to drug-free rehabilitation took up the offer, refusing treatment after they had learnt that they would not receive methadone. There were two placebo controlled trials (<LINK REF="STD-Newman-1979" TYPE="STUDY">Newman 1979</LINK>, <LINK REF="STD-Strain-1993a" TYPE="STUDY">Strain 1993a</LINK>). Finally, there have been six randomised clinical trials, three assessing methadone maintenance against methadone detoxification (<LINK REF="STD-Vanichseni-1991" TYPE="STUDY">Vanichseni 1991</LINK>, <LINK REF="STD-Sees-2000" TYPE="STUDY">Sees 2000</LINK>, <LINK REF="STD-Gruber-2008" TYPE="STUDY">Gruber 2008</LINK>) and the others assessing methadone maintenance against a wait-list control (<LINK REF="STD-Yancovitz-1991" TYPE="STUDY">Yancovitz 1991</LINK>, <LINK REF="STD-Dolan-2003" TYPE="STUDY">Dolan 2003</LINK>, <LINK REF="STD-Schwartz-2006" TYPE="STUDY">Schwartz 2006</LINK>).</P>
<P>Three studies were conducted in a prison setting (<LINK REF="STD-Dole-1969" TYPE="STUDY">Dole 1969</LINK>, <LINK REF="STD-Dolan-2003" TYPE="STUDY">Dolan 2003</LINK>, <LINK REF="STD-Kinlock-2007" TYPE="STUDY">Kinlock 2007</LINK>). The remainder were conducted in medical or research facilities.</P>
<P>The sample sizes in these studies were sometimes small, in that two studies having sample sizes of 32 and 34 (<LINK REF="STD-Dole-1969" TYPE="STUDY">Dole 1969</LINK>, <LINK REF="STD-Gunne-1981" TYPE="STUDY">Gunne 1981</LINK>), respectively. The remaining seven studies had sample sizes ranging from 100 to 240 (<LINK REF="STD-Newman-1979" TYPE="STUDY">Newman 1979</LINK>, <LINK REF="STD-Vanichseni-1991" TYPE="STUDY">Vanichseni 1991</LINK>, <LINK REF="STD-Sees-2000" TYPE="STUDY">Sees 2000</LINK>, <LINK REF="STD-Gruber-2008" TYPE="STUDY">Gruber 2008</LINK>) patients up to 247 to 382 patients (<LINK REF="STD-Strain-1993a" TYPE="STUDY">Strain 1993a</LINK>, <LINK REF="STD-Yancovitz-1991" TYPE="STUDY">Yancovitz 1991</LINK>, <LINK REF="STD-Dolan-2003" TYPE="STUDY">Dolan 2003</LINK>, <LINK REF="STD-Schwartz-2006" TYPE="STUDY">Schwartz 2006</LINK>).</P>
<P>The dosages of methadone used in these studies appears to have been adequate. In the first study, (<LINK REF="STD-Dole-1969" TYPE="STUDY">Dole 1969</LINK>) the dose at release from prison was 35 milligrams but patients were entered into a community program where blockade doses of approximately 100 milligrams were standard. In the study by Gunne (<LINK REF="STD-Gunne-1981" TYPE="STUDY">Gunne 1981</LINK>) the doses are not clearly stated. The placebo-controlled study by Newman (<LINK REF="STD-Newman-1979" TYPE="STUDY">Newman 1979</LINK>) have an average dose on 97 milligrams per day. An average of 74 milligrams per day was reported in the study from Thailand (<LINK REF="STD-Vanichseni-1991" TYPE="STUDY">Vanichseni 1991</LINK>). Strain (<LINK REF="STD-Strain-1993a" TYPE="STUDY">Strain 1993a</LINK>) used doses of methadone of 50 and 20 milligrams per day. The study by Dolan (<LINK REF="STD-Dolan-2003" TYPE="STUDY">Dolan 2003</LINK>) had a mean methadone dose of 61mg. The study by Schwartz (<LINK REF="STD-Schwartz-2006" TYPE="STUDY">Schwartz 2006</LINK>) had a mean dose of 78.4mg and Sees (<LINK REF="STD-Sees-2000" TYPE="STUDY">Sees 2000</LINK>) had a mean methadone dose of 86.3mg. The study by Gruber (<LINK REF="STD-Gruber-2008" TYPE="STUDY">Gruber 2008</LINK>) used a methadone dose range of 60-90mg and Kinlock (<LINK REF="STD-Kinlock-2007" TYPE="STUDY">Kinlock 2007</LINK>) set a target dose of 60mg. Finally, the study by Yancovitz (<LINK REF="STD-Yancovitz-1991" TYPE="STUDY">Yancovitz 1991</LINK>) used a maintenance dose of approximately 80 milligrams per day. As such, the results from the studies appear to use moderate to high doses on average.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of the trials</HEADING>
<P>As shown in the table of included studies, the interventions generally lasted for significant time of several weeks up to two years, although one study only ran 45 days (<LINK REF="STD-Vanichseni-1991" TYPE="STUDY">Vanichseni 1991</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Countries in which the studies were conducted</HEADING>
<P>The studies were conducted in a range of countries including; USA (<LINK REF="STD-Dole-1969" TYPE="STUDY">Dole 1969</LINK>, <LINK REF="STD-Yancovitz-1991" TYPE="STUDY">Yancovitz 1991</LINK>, <LINK REF="STD-Strain-1993a" TYPE="STUDY">Strain 1993a</LINK>, <LINK REF="STD-Sees-2000" TYPE="STUDY">Sees 2000</LINK>, <LINK REF="STD-Schwartz-2006" TYPE="STUDY">Schwartz 2006</LINK>, <LINK REF="STD-Gruber-2008" TYPE="STUDY">Gruber 2008</LINK>), Sweden <LINK REF="STD-Gunne-1981" TYPE="STUDY">Gunne 1981</LINK>), Australia (<LINK REF="STD-Dolan-2003" TYPE="STUDY">Dolan 2003</LINK>), Hong Kong (<LINK REF="STD-Newman-1979" TYPE="STUDY">Newman 1979</LINK>) and Thailand (<LINK REF="STD-Vanichseni-1991" TYPE="STUDY">Vanichseni 1991</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The participants (N=1969) were largely typical of heroin dependant individuals, in terms of age and gender characteristics. In some studies, only males were included but where females were included the gender distribution was as one would expect, with majority of the participants being male. They tended to be approximately 30 to 40 years of age, often unemployed and unmarried, with previous treatment histories and prevalence of use of other drugs, consistent with what is known about heroin users presenting for treatment.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Types of comparisons</HEADING>
<P>The review compared methadone maintenance treatment with no methadone maintenance treatment. All studies were assessed to determine whether they provided data on retention in treatment, codeable results from urine/hair analysis, self-reported drug use (particularly heroin use), criminal activity and mortality. After reviewing the studies, it was realised that it was not possible to include urine/hair results for cocaine and benzodiazepines as these were not reported in an analysable form for most studies. It was not possible to analyse data on either cocaine or benzodiazepine positive urines from these studies. However, it was possible to code data on retention in treatment, morphine positive urine or hair analysis, self-reported heroin use, criminal activity and mortality.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-03-09 22:23:08 +0100" MODIFIED_BY="[Empty name]">
<P>Three studies were not included. Refer to the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for the reason for exclusion.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-03-05 14:50:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<ALLOCATION MODIFIED="2009-03-05 14:48:36 +0100" MODIFIED_BY="[Empty name]">
<P>The study conducted by Dole (<LINK REF="STD-Dole-1969" TYPE="STUDY">Dole 1969</LINK>) had inadequate sequence generation for randomisation and was unclear on the concealment of allocation. The studies conducted by <LINK REF="STD-Sees-2000" TYPE="STUDY">Sees 2000</LINK>, <LINK REF="STD-Dolan-2003" TYPE="STUDY">Dolan 2003</LINK>, <LINK REF="STD-Schwartz-2006" TYPE="STUDY">Schwartz 2006</LINK>, <LINK REF="STD-Gruber-2008" TYPE="STUDY">Gruber 2008</LINK> and <LINK REF="STD-Kinlock-2007" TYPE="STUDY">Kinlock 2007</LINK> had adequate sequence generation for randomisation. The study by <LINK REF="STD-Dolan-2003" TYPE="STUDY">Dolan 2003</LINK> also had adequate concealment of allocation, as did the studies by <LINK REF="STD-Yancovitz-1991" TYPE="STUDY">Yancovitz 1991</LINK> and <LINK REF="STD-Newman-1979" TYPE="STUDY">Newman 1979</LINK>. It was unclear if the remaining studies had adequate sequence generation and concealment of allocation.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-03-05 14:49:36 +0100" MODIFIED_BY="[Empty name]">
<P>Of the eleven studies included in this review, two were placebo-controlled trials (<LINK REF="STD-Newman-1979" TYPE="STUDY">Newman 1979</LINK>, <LINK REF="STD-Strain-1993a" TYPE="STUDY">Strain 1993a</LINK>). Both of these studies were double-blind but <LINK REF="STD-Strain-1993a" TYPE="STUDY">Strain 1993a</LINK> did not provide sufficient data to be confident about the concealment of allocation. The remaining studies were not blinded.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-03-05 14:50:49 +0100" MODIFIED_BY="[Empty name]">
<P>All studies addressed the issue of incomplete outcome data adequately and were independently deemed by reviewers to be free of other major bias (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</EXCLUSIONS>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-03-09 11:30:20 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Results of meta-analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison 01 Methadone maintenance treatment versus no methadone maintenance treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Retention in treatment:</HEADING>
<P>7 studies; 1287 participants (<LINK REF="STD-Gruber-2008" TYPE="STUDY">Gruber 2008</LINK>, <LINK REF="STD-Kinlock-2007" TYPE="STUDY">Kinlock 2007</LINK>, <LINK REF="STD-Newman-1979" TYPE="STUDY">Newman 1979</LINK>, <LINK REF="STD-Schwartz-2006" TYPE="STUDY">Schwartz 2006</LINK>, <LINK REF="STD-Sees-2000" TYPE="STUDY">Sees 2000</LINK>, <LINK REF="STD-Strain-1993a" TYPE="STUDY">Strain 1993a</LINK>, <LINK REF="STD-Vanichseni-1991" TYPE="STUDY">Vanichseni 1991</LINK>). The relative risk on a random effect model was applied. The chi-square test for heterogeneity was significant (p&lt;0001) so a pooled estimate is not reported. However, the results from all studies showed that methadone has a superior retention rate compared with control conditions.Subgroup analysis was conducted examining the older studies (pre 2000) and the more recent studies, as differences in results can occur over time. The heterogeneity for the older studies (<LINK REF="STD-Newman-1979" TYPE="STUDY">Newman 1979</LINK>, <LINK REF="STD-Strain-1993a" TYPE="STUDY">Strain 1993a</LINK>, <LINK REF="STD-Vanichseni-1991" TYPE="STUDY">Vanichseni 1991</LINK>; 3 studies, 505 patients) was significant, as indicated in the previous published review. (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.1). Data from the newer studies (<LINK REF="STD-Gruber-2008" TYPE="STUDY">Gruber 2008</LINK>, <LINK REF="STD-Kinlock-2007" TYPE="STUDY">Kinlock 2007</LINK>, <LINK REF="STD-Schwartz-2006" TYPE="STUDY">Schwartz 2006</LINK>, <LINK REF="STD-Sees-2000" TYPE="STUDY">Sees 2000</LINK>) show the superiority of methadone over control in retaining patients in treatment (4 studies, 750 patients, RR=4.44, 95% CI:3.26-2.04). The test for heterogeneity was not significant (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2 Morphine positive urine or hair analysis</HEADING>
<P>6 studies, 1129 participants (<LINK REF="STD-Dolan-2003" TYPE="STUDY">Dolan 2003</LINK>, <LINK REF="STD-Gruber-2008" TYPE="STUDY">Gruber 2008</LINK>, <LINK REF="STD-Kinlock-2007" TYPE="STUDY">Kinlock 2007</LINK>, <LINK REF="STD-Schwartz-2006" TYPE="STUDY">Schwartz 2006</LINK>, <LINK REF="STD-Vanichseni-1991" TYPE="STUDY">Vanichseni 1991</LINK>, <LINK REF="STD-Yancovitz-1991" TYPE="STUDY">Yancovitz 1991</LINK>). Turning to the data from morphine positive urine/ hair analysis, five studies (<LINK REF="STD-Vanichseni-1991" TYPE="STUDY">Vanichseni 1991</LINK>, <LINK REF="STD-Yancovitz-1991" TYPE="STUDY">Yancovitz 1991</LINK>, <LINK REF="STD-Dolan-2003" TYPE="STUDY">Dolan 2003</LINK>, <LINK REF="STD-Schwartz-2006" TYPE="STUDY">Schwartz 2006</LINK>, <LINK REF="STD-Gruber-2008" TYPE="STUDY">Gruber 2008</LINK>) provided dichotomous data as to whether patients had morphine positive urine/hair at follow up. The results from these studies providing data on the presence/absence of morphine in urine at the follow-up showed an advantage of methadone above the control conditions (6 studies, 1129 patients RR = 0.66, 95% CI 0.56-0.78), in this case detoxification, wait-list or control, in reducing heroin use as shown by a lack of heroin metabolites in urine or hair. (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3 Self-reported heroin use</HEADING>
<P>6 studies, 682 participants (<LINK REF="STD-Dolan-2003" TYPE="STUDY">Dolan 2003</LINK>, <LINK REF="STD-Dole-1969" TYPE="STUDY">Dole 1969</LINK>, <LINK REF="STD-Gruber-2008" TYPE="STUDY">Gruber 2008</LINK>, <LINK REF="STD-Gunne-1981" TYPE="STUDY">Gunne 1981</LINK>, <LINK REF="STD-Kinlock-2007" TYPE="STUDY">Kinlock 2007</LINK>, <LINK REF="STD-Vanichseni-1991" TYPE="STUDY">Vanichseni 1991</LINK>). The results from the objective data on morphine positive urine/hair analysis were also supported by self-report data from five studies. In particular, studies from the USA, Sweden and Australia (<LINK REF="STD-Dole-1969" TYPE="STUDY">Dole 1969</LINK>, <LINK REF="STD-Gunne-1981" TYPE="STUDY">Gunne 1981</LINK>, <LINK REF="STD-Yancovitz-1991" TYPE="STUDY">Yancovitz 1991</LINK>, <LINK REF="STD-Dolan-2003" TYPE="STUDY">Dolan 2003</LINK>, <LINK REF="STD-Kinlock-2007" TYPE="STUDY">Kinlock 2007</LINK>) all concurred to show an advantage for methadone above control in reduction of heroin use as reported by the patients. The study by <LINK REF="STD-Gruber-2008" TYPE="STUDY">Gruber 2008</LINK> showed no difference between groups. The test for heterogeneity was significant (p&lt;0.000001) so a pooled estimate is not reported. (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4 Criminal activity</HEADING>
<P>3 studies, 363 participants (<LINK REF="STD-Dole-1969" TYPE="STUDY">Dole 1969</LINK>, <LINK REF="STD-Gunne-1981" TYPE="STUDY">Gunne 1981</LINK>, <LINK REF="STD-Yancovitz-1991" TYPE="STUDY">Yancovitz 1991</LINK>). The results for the criminal activity variable, available for three studies, were consistent with the reduction in heroin use, even though the advantage for methadone beyond control in reducing criminal activity was not statistically significant (3 studies, 363 patients RR=0.39, 95% CI:0.12-1.25). The test for heterogeneity was not significant. (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5 Mortality</HEADING>
<P>4 studies, 576 participants (<LINK REF="STD-Gunne-1981" TYPE="STUDY">Gunne 1981</LINK>, <LINK REF="STD-Kinlock-2007" TYPE="STUDY">Kinlock 2007</LINK>, <LINK REF="STD-Newman-1979" TYPE="STUDY">Newman 1979</LINK>, <LINK REF="STD-Yancovitz-1991" TYPE="STUDY">Yancovitz 1991</LINK>). Turning finally to the evidence concerning the ability of methadone to prevent deaths, available for four studies, the results showed a trend in favour of methadone that was not statistically significant (4 studies, 576 patients RR=0.48, 95% CI: 0.10-2.39). (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>)<BR/>
<BR/>Other measures (e.g., use of other drugs, physical health, and psychological health) are too infrequently and irregularly reported in the literature to be usefully integrated in the quantitative review.</P>
<P>The results are also summarized in the Summary of findings table 1 </P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-03-05 14:59:28 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2009-03-05 14:56:49 +0100" MODIFIED_BY="[Empty name]">
<P>The results of the meta-analysis indicate that methadone is able to retain patients in treatment better than the drug-free alternatives (placebo medication, offer of drug-free treatment, detoxification, or wait-list control), to suppress heroin use based on morphine (the heroin metabolite) found in urine/hair samples, and patient self-report. There was a greater reduction in criminal activity and mortality among the MMT patients, but these differences were not statistically significant. There is evidence from other literature showing mortality (<LINK REF="REF-Gibson-2008" TYPE="REFERENCE">Gibson 2008</LINK>, <LINK REF="REF-Clausen-2008" TYPE="REFERENCE">Clausen 2008</LINK>) and criminal activity (<LINK REF="REF-Lind-2005" TYPE="REFERENCE">Lind 2005</LINK>) is decreased in patients who are in methadone treatment.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-03-05 14:58:10 +0100" MODIFIED_BY="[Empty name]">
<P>Interestingly, the results from these eleven randomised trials all showed statistically significant positive benefits from methadone treatment, despite their small sample sizes. Additional support for the efficacy of methadone maintenance treatment comes from the results of many observational studies wherein some statistical form of control has addressed alternative explanations of apparent effectiveness. These large scale observational studies have generally supported the results from the randomised clinical trials in showing that methadone maintenance treatment reduces the use of heroin and decreases criminal activity (<LINK REF="REF-Ward-1998" TYPE="REFERENCE">Ward 1998</LINK>). As noted earlier there is a broader international literature showing advantages for methadone beyond other treatments in terms of reduction of death (<LINK REF="REF-Ward-1998" TYPE="REFERENCE">Ward 1998</LINK>), even though the randomised trial data do not show this result.</P>
<P>Another relevant outcome to be considered would be seroconversion for HIV, which is the object of a separate Cochrane review (<LINK REF="REF-Gowing-2004" TYPE="REFERENCE">Gowing 2004</LINK>). Methadone maintenance treatment has been shown to reduce HIV risk taking behaviour (specifically reduction in needle sharing) and thereby has achieved a reduction in the transmission of HIV. Consistent with this it has been shown that methadone maintenance treatment is protective of patients, reducing HIV infection in geographic locations where HIV had spread rapidly among injecting drug users who had not entered treatment. We have commented elsewhere on two large prospective cohort studies in the USA which found methadone maintenance treatment protected against HIV infection (<LINK REF="REF-Ward-1998" TYPE="REFERENCE">Ward 1998</LINK>). This outcome could not be addressed here as there are no randomised trials of methadone that have included HIV status as a measure, the evidence coming from observational studies.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-03-05 14:59:06 +0100" MODIFIED_BY="[Empty name]">
<P>It is notable that the doses of methadone used in the randomised clinical trials are probably slightly higher than are being used currently in routine clinical practice in some parts of the world. This relative underdosing in clinical practice may lead to a reduction in the effectiveness of methadone, as the response to methadone treatment is dose-dependent. In addition, it is important to recognise that methadone treatment in these trials was often provided with substantial ancillary services. These ancillary services have included counselling, psycho-social services, medical services and often psychiatric care. The quality of the therapeutic relationship with staff in methadone clinics plus the intensity of these ancillary services, combined with the dose of methadone prescribed will all act to enhance the outcome for methadone treatment. The extent that clinical programs move away from such an approach might be expected to impact on the effectiveness of methadone.</P>
<P>This does not imply that methadone maintenance treatment will become ineffective. Even allowing for some reduction in effectiveness when methadone is not provided in the fashion that it has been in the clinical trials, it is still likely to be effective. The effects of methadone may be modest, if they are judged by unrealistic expectations of patients can easily achieve enduring abstinence from opioid drugs. Methadone nonetheless attracts and retains more patients than alternative treatments, and it does produce better outcomes amongst those who complete treatment. Methadone maintenance appears to provide better outcomes than simple detoxification programs, where the evidence suggests that short-term detoxification has no enduring effect on drug use (<LINK REF="REF-Mattick-1996" TYPE="REFERENCE">Mattick 1996</LINK>).</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The implications of the results of the meta-analytic review conducted and reported herein for clinical practice are that methadone maintenance treatment is an effective intervention for the management of heroin dependence. Methadone retains patients in treatment and reduces heroin use. Methadone should be supported as a maintenance treatment for heroin dependence. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Overall there are a relatively limited number of randomised clinical trials on the efficacy of methadone treatment compared to placebo. It does not seem feasible at this stage to conduct further randomised trials of methadone treatment. However, evidence on reduction of criminal activity and mortality from clinical trials is lacking calling for an additional systematic review of observational studies. Moreover, monitoring of the outcome of standard methadone treatment in clinical practice may be important as a research activity to demonstrate its ongoing effectiveness, or to determine whether its effectiveness is being compromised through the reduction of ancillary services or reduction in adequate dose levels. </P>
<P>A number of measures (e.g., of other drug use, physical health, and psychological health) were too infrequently and irregularly reported in the literature to be usefully integrated in the quantitative review, but future research might address these important areas. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-03-05 15:01:23 +0100" MODIFIED_BY="[Empty name]">
<P>We acknowledge the assistance of the Cochrane Review Group Coordinating Centre, Rome.</P>
<P>Laura Amato from the Rome Editorial Base provided copyediting on the drafts of this review.</P>
<P>Marica Ferri from the Rome Editorial Base provided comments and copyediting on the drafts of the previous version of the review as well as Roberto D'Amico from the Cochrane Statistical Methods Group provided advice on statistical analysis issues.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-01-17 02:27:16 +0100" MODIFIED_BY="[Empty name]">
<P>The first reviewer, Richard P. Mattick, is the fourth author on the Australian trial of methadone maintenance versus wait-list control in a prison setting (<LINK REF="STD-Dolan-2003" TYPE="STUDY">Dolan 2003</LINK>).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-01-27 04:26:03 +0100" MODIFIED_BY="[Empty name]">
<P>Contributions: Richard P Mattick, Jo Klimber and Courtney Breen reviewed the papers, with Courtney Breen and Richard P. Mattick coding data from the papers for meta-analysis.</P>
<P>Richard P. Mattick conceptualised the review and Courtney Breen conducted the initial literature searches.</P>
<P>Richard P. Mattick wrote the analysis sections and discussion. Marina Davoli was the contact editor of the review and contributed to the writing of the final version of the review.</P>
<P>The review was updated by Richard P. Mattick and Courtney Breen. </P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-04-07 10:32:38 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-03-05 15:16:36 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-03-05 15:11:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Dolan-2003" MODIFIED="2009-03-05 15:04:55 +0100" MODIFIED_BY="[Empty name]" NAME="Dolan 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-03-05 15:04:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak A</AU>
<TI>A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2003</YR>
<VL>72</VL>
<PG>59-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dole-1969" MODIFIED="2009-03-05 15:05:12 +0100" MODIFIED_BY="[Empty name]" NAME="Dole 1969" YEAR="1969">
<REFERENCE MODIFIED="2009-03-05 15:05:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Dole V, Robinson J, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. New England Journal of Medicine 1969; 280: 1372-1375.&lt;/p&gt;" NOTES_MODIFIED="2009-03-05 15:05:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dole V, Robinson J, Orraca J, Towns E, Searcy P, Caine E</AU>
<TI>Methadone treatment of randomly selected criminal addicts</TI>
<SO>New England Journal of Medicine</SO>
<YR>1969</YR>
<VL>280</VL>
<PG>1372-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gruber-2008" MODIFIED="2009-03-05 15:05:32 +0100" MODIFIED_BY="[Empty name]" NAME="Gruber 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-03-05 15:05:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gruber VA, Delucchi KL, Kielstein A, Batki SL</AU>
<TI>A randomised trial of 6-month methadone maintenance with standard or minimal counselling versus 21-day methadone detoxification.</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2008</YR>
<VL>94</VL>
<PG>199-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gunne-1981" MODIFIED="2009-03-05 15:05:46 +0100" MODIFIED_BY="[Empty name]" NAME="Gunne 1981" YEAR="1981">
<REFERENCE MODIFIED="2009-03-05 15:05:46 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Gunne L, Gronbladh L. The Swedish methadone maintenance program: A controlled study. Drug and Alcohol Dependence 1981; 7: 249-256.&lt;/p&gt;" NOTES_MODIFIED="2009-03-05 15:05:46 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gunne L, Gronbladh L</AU>
<TI>The Swedish methadone maintenance program: A controlled study</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1981</YR>
<VL>7</VL>
<PG>249-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinlock-2007" MODIFIED="2009-03-05 15:06:01 +0100" MODIFIED_BY="[Empty name]" NAME="Kinlock 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-03-05 15:06:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinlock TW, Gordon MS, Schwartz RP, O'Grady K, Fitzgerald TT, Wilson M</AU>
<TI>A randomised clinical trial of methadone maintenance for prisoners: Results at 1 month post release</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2007</YR>
<VL>91</VL>
<PG>220-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newman-1979" MODIFIED="2009-03-05 15:06:11 +0100" MODIFIED_BY="[Empty name]" NAME="Newman 1979" YEAR="1979">
<REFERENCE MODIFIED="2009-03-05 15:06:11 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Newman R, Whitehill W. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 1979; 485-488.&lt;/p&gt;" NOTES_MODIFIED="2009-03-05 15:06:11 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newman R, Whitehill W</AU>
<TI>Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong</TI>
<SO>Lancet</SO>
<YR>1979</YR>
<VL>September 8</VL>
<PG>485-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-2006" MODIFIED="2009-03-05 15:06:47 +0100" MODIFIED_BY="[Empty name]" NAME="Schwartz 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-05 15:06:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CB, Rouse CO, et al</AU>
<TI>A randomised controlled trial of interim methadone maintenance</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<PG>102-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sees-2000" MODIFIED="2009-03-05 15:07:11 +0100" MODIFIED_BY="[Empty name]" NAME="Sees 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-03-05 15:07:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, et al</AU>
<TI>Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence. A randomised controlled trial</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2000</YR>
<VL>283</VL>
<NO>10</NO>
<PG>1303-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strain-1993a" MODIFIED="2009-03-05 15:07:18 +0100" MODIFIED_BY="[Empty name]" NAME="Strain 1993a" YEAR="1993">
<REFERENCE MODIFIED="2009-03-05 15:07:18 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Strain E, Stitzer M, Leibson I, Bigelow G. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med. 1993: 119: 23-27.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-03-05 15:07:18 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strain E, Stitzer M, Leibson I, Bigelow G</AU>
<TI>Dose-response effects of methadone in the treatment of opioid dependence</TI>
<SO>Ann Intern Med</SO>
<YR>1993</YR>
<VL>119</VL>
<PG>23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanichseni-1991" MODIFIED="2009-03-05 15:10:07 +0100" MODIFIED_BY="[Empty name]" NAME="Vanichseni 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-03-05 15:10:07 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Vanichseni S, Wongsuwan B, The Staff of BMA Narcotics Clinic No.6, Choopanya K, Wongpanich K. A controlled trial of methadone in a population of intravenous drug users in Bangkok: implications for prevention of HIV. The International Journal of the Addictions 1991; 26(12): 1313-1320.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-03-05 15:10:07 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanichseni S, Wongsuwan B, Choopanya K, Wongpanich K</AU>
<TI>A controlled trial of methadone in a population of intravenous drug users in Bangkok: implications for prevention of HIV</TI>
<SO>International Journal of the Addictions</SO>
<YR>1991</YR>
<VL>26</VL>
<NO>12</NO>
<PG>1313-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yancovitz-1991" MODIFIED="2009-03-05 15:11:35 +0100" MODIFIED_BY="[Empty name]" NAME="Yancovitz 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-03-05 15:11:35 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Yancovitz S, Des Jarlais D, Peskoe Peyser N, Drew E, Friedman P, Trigg H, Robinson J. A randomized trial of an interim methadone maintenance clinic. Am. J of Pub Health 1991; 81: 1185 - 1191.&lt;/p&gt;" NOTES_MODIFIED="2009-03-05 15:11:35 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yancovitz S, Des Jarlais D, Peskoe Peyser N, Drew E, Friedman P, Trigg H, et al</AU>
<TI>A randomised trial of an interim methadone maintenance clinic</TI>
<SO>Am J of Pub Health</SO>
<YR>1991</YR>
<VL>81</VL>
<PG>1185-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-03-05 15:16:36 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bale-1980" MODIFIED="2009-03-05 15:11:48 +0100" MODIFIED_BY="[Empty name]" NAME="Bale 1980" YEAR="1980">
<REFERENCE MODIFIED="2009-03-05 15:11:48 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bale R, Van Stone W, Kuldau J, Engelsing T, Elashoff R &amp;amp; Zarcone V. Therapeutic communities vs methadone maintenance. A prospective controlled study of narcotic addiction treatment: design and one year follow-up. Archives of General Psychiatry; 37: 179-193.&lt;/p&gt;" NOTES_MODIFIED="2009-03-05 15:11:48 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bale R, Van Stone W, Kuldau J, Engelsing T, Elashoff R, Zarcone V</AU>
<TI>Therapeutic communities vs methadone maintenance. A prospective controlled study of narcotic addiction treatment: design and one year follow-up</TI>
<SO>Arch Gen Psych</SO>
<YR>1980</YR>
<VL>37</VL>
<PG>179-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dolan-2005" MODIFIED="2009-03-05 15:12:00 +0100" MODIFIED_BY="[Empty name]" NAME="Dolan 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-05 15:12:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak A</AU>
<TI>Four-year follow up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection</TI>
<SO>Addiction</SO>
<YR>2005</YR>
<VL>100</VL>
<PG>820-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-2007" MODIFIED="2009-03-05 15:16:36 +0100" MODIFIED_BY="[Empty name]" NAME="Schwartz 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-03-05 15:16:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz RP, Jaffe JH, Highfield DA, Callaman JM, O'Grady KE</AU>
<TI>A randomized controlled trial of interim methadone maintenance: 10-month follow-up</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2007</YR>
<VL>86</VL>
<PG>30-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-04-07 10:32:38 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-04-07 10:32:38 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Clausen-2008" MODIFIED="2009-03-05 15:17:09 +0100" MODIFIED_BY="[Empty name]" NAME="Clausen 2008" TYPE="JOURNAL_ARTICLE">
<AU>Clausen T, Anchersen K, Waal H</AU>
<TI>Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross-registry study</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2008</YR>
<VL>94</VL>
<PG>151-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooper-1983" MODIFIED="2009-03-05 15:20:32 +0100" MODIFIED_BY="[Empty name]" NAME="Cooper 1983" TYPE="BOOK">
<AU>Cooper J, Altman F, Brown, B, Czechowicz D</AU>
<SO>Research on the treatment of narcotic addiction: State of the art</SO>
<YR>1983</YR>
<PB>National Institute on Drug Abuse</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dole-1965" MODIFIED="2009-03-05 15:21:31 +0100" MODIFIED_BY="[Empty name]" NAME="Dole 1965" TYPE="JOURNAL_ARTICLE">
<AU>Dole V, Nyswander M</AU>
<TI>A medical treatment of diacetylmorphine (heroin) addiction</TI>
<SO>JAMA</SO>
<YR>1965</YR>
<VL>193</VL>
<PG>80-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dole-Nyswander-1967" MODIFIED="2009-03-05 15:20:48 +0100" MODIFIED_BY="[Empty name]" NAME="Dole Nyswander 1967" TYPE="JOURNAL_ARTICLE">
<AU>Dole V, Nyswander M</AU>
<TI>Heroin addiction - a metabolic disease</TI>
<SO>Arch Internal Medicine</SO>
<YR>1967</YR>
<VL>120</VL>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gerstein-1990" MODIFIED="2009-03-05 15:20:54 +0100" MODIFIED_BY="[Empty name]" NAME="Gerstein 1990" TYPE="BOOK">
<AU>Gerstein D, Harwood H</AU>
<SO>Treating drug problems Volume 1: A study of effectiveness and financing of public and private drug treatment systems</SO>
<YR>1990</YR>
<PB>National Academy Press</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gibson-2008" MODIFIED="2009-03-05 15:30:58 +0100" MODIFIED_BY="[Empty name]" NAME="Gibson 2008" TYPE="JOURNAL_ARTICLE">
<AU>Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O'Brien S</AU>
<TI>Exposure to opioid maintenance treatment reduces long-term mortality</TI>
<SO>Addiction</SO>
<YR>2008</YR>
<VL>103</VL>
<PG>462-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gowing-2004" MODIFIED="2009-03-05 15:50:15 +0100" MODIFIED_BY="[Empty name]" NAME="Gowing 2004" TYPE="COCHRANE_REVIEW">
<AU>Gowing L, Farrell M, Bornemann R, Ali R</AU>
<TI>Substitution treatment of injecting opioid users for prevention of HIV infection</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-03-05 15:50:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-05 15:50:15 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004145"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hargreaves-1983" MODIFIED="2009-03-05 15:50:24 +0100" MODIFIED_BY="[Empty name]" NAME="Hargreaves 1983" TYPE="BOOK_SECTION">
<AU>Hargreaves W</AU>
<TI>Methadone dosage and duration for maintenance treatment.</TI>
<SO>Research on the treatment of narcotic addiction: State of the art</SO>
<YR>1983</YR>
<ED>J Cooper , F Altman, B Brown, D Czechowicz</ED>
<PB>National Institute on Drug Abuse</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" MODIFIED="2009-04-07 10:31:55 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2006" TYPE="OTHER">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5</TI>
<SO>The Cochrane Library 2006;(3)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-04-07 10:32:38 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated February 2008]. The Cochrane Collaboration, 2008</TI>
<SO>www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jaffe-1990" MODIFIED="2009-03-05 15:50:32 +0100" MODIFIED_BY="[Empty name]" NAME="Jaffe 1990" TYPE="BOOK_SECTION">
<AU>Jaffe, J</AU>
<TI>Drug addiction and drug abuse</TI>
<SO>The pharmacological basis of therapeutics</SO>
<YR>1990</YR>
<PG>522-73</PG>
<EN>8th</EN>
<ED>A Gilman, T Rall, A Nies, P Taylor</ED>
<PB>Pergamon Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lind-2005" MODIFIED="2009-03-05 15:51:29 +0100" MODIFIED_BY="[Empty name]" NAME="Lind 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lind B, Chen S, Weatherburn D, Mattick R</AU>
<TI>The effectiveness of methadone maintenance treatment in controlling crime. An Australian aggregate-level analysis</TI>
<SO>Journal of Criminology</SO>
<YR>2005</YR>
<VL>45</VL>
<PG>201-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mattick-1993" MODIFIED="2009-03-05 15:21:12 +0100" MODIFIED_BY="[Empty name]" NAME="Mattick 1993" TYPE="BOOK">
<AU>Mattick R P, Hall W</AU>
<SO>A treatment outline for approaches to opioid dependence: Quality assurance project</SO>
<YR>1993</YR>
<PB>Australian Government Publishing Service</PB>
<CY>Canberra</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mattick-1996" NAME="Mattick 1996" TYPE="JOURNAL_ARTICLE">
<AU>Mattick RP, Hall W</AU>
<TI>Are detoxification programmes effective?</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<PG>97-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ward-1992" MODIFIED="2009-03-05 15:21:18 +0100" MODIFIED_BY="[Empty name]" NAME="Ward 1992" TYPE="BOOK">
<AU>Ward J, Mattick R P, Hall W</AU>
<SO>Key issues in methadone maintenance treatment</SO>
<YR>1992</YR>
<PB>New South Wales University Press</PB>
<CY>Sydney</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ward-1998" MODIFIED="2009-01-17 02:24:11 +0100" MODIFIED_BY="[Empty name]" NAME="Ward 1998" TYPE="BOOK">
<AU>Ward J, Mattick R.P, Hall W. M</AU>
<SO>Methadone Maintenance Treatment and Other Opioid Replacement Therapies</SO>
<YR>1998</YR>
<PB>Harwood Academic Publishers</PB>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-02-10 04:20:34 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-02-10 04:20:34 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-01-24 01:09:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dolan-2003">
<CHAR_METHODS MODIFIED="2009-01-17 03:04:42 +0100" MODIFIED_BY="[Empty name]">
<P>Two group, open, randomised controlled trial. Randomisation: in blocks of ten by randomly drawing cards from an envelope. List of case numbers and group allocation not known to researcher or trial nurse. Follow up for four months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-24 01:09:34 +0100" MODIFIED_BY="[Empty name]">
<P>Geographic region: Australia</P>
<P>Study setting: Prison. Participants were inmates on a waiting list for MMT.</P>
<P>n = 382 males<BR/>mean age = 27 years<BR/>Eligibility criteria: heroin problem confirmed by medical interview, serving sentences of more than four months, and able to provide informed consent.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-17 02:59:27 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: methadone maintenance treatment - flexible dose (mean 61mg, range 1-180mg).<BR/>Control: wait-list.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-17 02:59:43 +0100" MODIFIED_BY="[Empty name]">
<P>Heroin use - Hair analysis and self report. Syringe sharing. HIV and HCV seroprevalence.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-24 01:22:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dole-1969">
<CHAR_METHODS MODIFIED="2009-01-17 04:37:29 +0100" MODIFIED_BY="[Empty name]">
<P>Two group, open, randomised controlled trial. Randomisation: release dates of treatment applicants were selected by lottery. Applicants who were not selected and demonstrated motivation for treatment became untreated controls. Follow-up for 50 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-24 01:22:42 +0100" MODIFIED_BY="[Empty name]">
<P>Geographic region: USA</P>
<P>Study setting: Prison. Participants were inmates eligible for release over a four month period from New York City Correctional Institute for Men.<BR/>n = 32 males<BR/>mean age = 30 years<BR/>15% European descent, 10% African American, 7% Hispanic<BR/>Eligibility criteria: heroin dependence for 5 or more years, record of 5 or more previous convictions, not committed to custody of Addiction Services Agency.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: wait-list<BR/>Treatment: 10 day methadone maintenance pre-release. <BR/>Initial dose 10 mg, increasing to 35 mg at release. <BR/>Continued methadone maintenance in outpatient clinic after release.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Urinalysis (weekly for heroin, amphetamines, cocaine, barbituates and alcohol)<BR/>Employment / education<BR/>Reincarceration</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-27 04:44:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gruber-2008">
<CHAR_METHODS MODIFIED="2009-01-17 03:03:43 +0100" MODIFIED_BY="[Empty name]">
<P>Three group randomised controlled trial. Randomisation: generated by statistician who placed assignments in sealed envelopes not revelaed to project staff. Allocation to group (21 day methadone detoxification, 6 months methadone with minimal counselling or 6 months methadone with standard couselling) revealed at conclusion of baseline interview.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-24 01:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>Geographic region: USA</P>
<P>Study setting Outpatient hospital detoxification program.</P>
<P>n=111, 68% male</P>
<P>mean age=41.9 years</P>
<P>54% White, 30% African American, 20% Hispanic, 4% Native American, 5% Asian/Pacific Islander</P>
<P>85% unmarried</P>
<P>Eligibility criteria; latent TB infection, DSM III R opioid dependence, aged 21-59, and willingness to receive isonaid preventive therapy and MMT. Excluded if pregnant or HIV positive or active liver disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-01-17 03:05:54 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: 6 months methadone maintenance with minimal or standard counselling, followed by 6 week taper. Control: 21 day methadone detoxification.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-17 03:06:05 +0100" MODIFIED_BY="[Empty name]">
<P>Retention<BR/>Illicit drug use - self report and urinalysis (monthly)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-01-27 04:44:14 +0100" MODIFIED_BY="[Empty name]">
<P>Results from the standard counseling and minimal counseling groups have been combined and compared to the detoxification group.</P>
<P>Unpublished data - the author provided additional data to enable the coding of retention and heroin use.</P>
<P>All participants have active TB infection - study part of a larger study examining TB.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-08 02:20:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gunne-1981">
<CHAR_METHODS MODIFIED="2009-02-08 02:20:24 +0100" MODIFIED_BY="[Empty name]">
<P>Two group randomised clinical trial. Randomisation: after eligibility established subjects were randomly allocated to methadone maintenance or to drug-free treatment. Foow up for two years.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-24 01:08:55 +0100" MODIFIED_BY="[Empty name]">
<P>Geographic region: Sweden</P>
<P>Study setting: psychiatric research centre</P>
<P>n = 34, 76% male<BR/>Eligibility criteria: 20-24 years, history of at least 4 years IV heroin use, withdrawal signs and positive urine on admission, a minimum of three completed detoxifications, not arrested or serving a sentence and no dominate abuse of non-opiate drugs. Exclusion: active infectious disease.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-08 02:19:33 +0100" MODIFIED_BY="[Empty name]">
<P>Control: no treatment, could not apply for the methadone program for two years.<BR/>Treatment: methadone maintenance treatment, no dosage information reported. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Illicit drug use / Urinalysis (3 x week)<BR/>Criminality<BR/>Vocational adjustment<BR/>Health<BR/>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-03-26 10:20:30 +0100" MODIFIED_BY="[Empty name]">
<P>2 controls obtained methadone from private practitioners and were excluded.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-08 02:16:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinlock-2007">
<CHAR_METHODS MODIFIED="2009-01-27 01:53:28 +0100" MODIFIED_BY="[Empty name]">
<P>Three group randomised controlled trial. Randomisation: after eligibility established subjects were randomly allocated to one of three groups. Randomisation process not described. Follow up for one month.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-24 01:20:06 +0100" MODIFIED_BY="[Empty name]">
<P>Geographic region: USA</P>
<P>Study setting: Prison. Participants were inmates due for release in 3-6 months.</P>
<P>n = 211 males<BR/>mean age =40.3 years</P>
<P>70% African American, 24% Caucasian<BR/>Eligibility criteria: DSM IV heroin dependence at time of incarceration, suitability for MMT as determined by medical assessment, willingness to enrol in prison MMT and residing in Baltimore on release. Individuals that did not meet dependence criteria were eligible if they had been enrolled in an opiate treatment program the year prior to incarceration.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-08 02:16:22 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: Counseling and methadone maintenance in prison with transfer into treatment on release. Target methadone dose 60mg.</P>
<P> Control: Counseling in prison with passive referal to treatment upon release</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-17 05:19:42 +0100" MODIFIED_BY="[Empty name]">
<P>Entry into community MMT<BR/>Illicit drug use - self report and urinalysis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-01-17 05:20:10 +0100" MODIFIED_BY="[Empty name]">
<P>A third group received counseling in prison and active referal to MMT on release group. These results have not been included in the analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-08 02:23:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newman-1979">
<CHAR_METHODS>
<P>Double blind randomised clinical trial<BR/>Randomisation: subjects randomly allocated on discharge from hospital after 2 week stabilisation on 60mg methadone to detoxification or continued maintenance.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-24 01:08:25 +0100" MODIFIED_BY="[Empty name]">
<P>Geographic region: Hong Kong<BR/>Study setting: Hospital and outpatient clinic</P>
<P>n = 100 males<BR/>mean age = 38 years<BR/>Eligibility criteria: male, 22-58 years, history of heroin dependence for at least 4 years and at least one previous treatment, current heroin dependence by three consecutive positive urine samples, voluntary application for admission (criminal justice referrals excluded), resident with fixed address, absence of past or present major psychiatric or medical illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-08 02:23:18 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: methadone maintenance - flexible dose (average 97 mg / day).<BR/>Control: detoxification from 60mg methadone at 1mg/day for 60 days, placebo thereafter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Illicit drug use / Urinalysis (daily collection, analysed 2 x week for morphine only)<BR/>Retention<BR/>Criminal activity<BR/>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-08 02:23:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwartz-2006">
<CHAR_METHODS MODIFIED="2009-01-24 00:34:20 +0100" MODIFIED_BY="[Empty name]">
<P>Two group randomised controlled trial with participants randomised to interim methadone maintenance treatment or a wait list control. Random assignment generated by random number table and sealed in an envelope.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-24 01:18:13 +0100" MODIFIED_BY="[Empty name]">
<P>Geographic region: USA</P>
<P>Study setting: community methadone treatment facility.<BR/>n=319, 59% male</P>
<P>mean age =41.4 years</P>
<P>93% African American</P>
<P>62% unemployed</P>
<P>Eligibility criteria; DSM IV heroin dependence and informed consent. Exclusions; pregnant or acute medical or psychiatric illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-08 02:23:45 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: interim methadone maintenance treatment for 120 days after which entry into a comprehensive methadone treatment program if unable to gain entry before 120 days. </P>
<P>Control: wait-list</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-17 03:07:25 +0100" MODIFIED_BY="[Empty name]">
<P>Entry into comprehensive methadone maintenance treatment at 4 months.<BR/>Illicit drug use /self report and urinalysis. Criminal activity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-01-17 03:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>Mobile program that at time of study administered methadone from specially equipped recreational vehicle</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-10 04:20:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sees-2000">
<CHAR_METHODS MODIFIED="2009-01-17 03:07:49 +0100" MODIFIED_BY="[Empty name]">
<P>Two group randomised controlled trial. Randomisation: participants randomly allocated from stratified blocks to methadone maintenance treatment or 180-day methadone assisted detoxification.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-24 01:14:06 +0100" MODIFIED_BY="[Empty name]">
<P>Geographic region: USA</P>
<P>Study setting: Medical Center<BR/>n=179, 59% male</P>
<P>mean age = 39.4 years</P>
<P>52% Caucasian, 30% African American, 13% Hispanic</P>
<P>53% unemployed, 79% unmarried<BR/>Eligibility criteria: opioid depeendent and urine screen positive for opioid and negative for methadone.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-08 02:16:48 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: methadone maintenance for 14 months followed by a 2 month detoxification. Participants required to attend 1hr/wk group therapy and 1hr/wk individual theray for first 6 months.<BR/>Flexible dose (max dose of 100mg/d)<BR/>Control: 14 months of substance abuse treatment. 120 days induction and methadone maintenance followed by 60 days of dose reductions. Participants were required to attend 2hr/wk group therapy, 1hr /week education classes and weekly individal therapy sessions. During month 7-14 participants offered nonmethadone aftercare treatment - group and individual therapy and liaison services with criminal justice, medical clinics and social services.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-10 04:20:02 +0100" MODIFIED_BY="[Empty name]">
<P>Retention <BR/>Illicit drug use - self report and monthly urinalysis.<BR/>HIV risk behaviours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-10 04:20:34 +0100" MODIFIED_BY="[Empty name]">
<P>Retention data was taken at 180 days from Fig 3 in the published paper. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-24 01:19:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strain-1993a">
<CHAR_METHODS MODIFIED="2008-03-26 10:20:36 +0100" MODIFIED_BY="[Empty name]">
<P>Three group, double-blind, placebo controlled randomised controlled trial. Patients were stratified by race and sex and randomly assigned to a fixed dose schedule at admission.<BR/>Treatment group assignment, stabilisation dose and dosing schedules were blind to patient and clinic staff with patient contact.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-24 01:19:00 +0100" MODIFIED_BY="[Empty name]">
<P>Geographic region: USA<BR/>Study setting: methadone treatment research clinic<BR/>n = 247, 70% male<BR/>mean age = 34 years<BR/>50% African American<BR/>62% unemployed, 84% unmarried<BR/>Eligibility criteria: 18-50 years, history of IV opioid dependence, no chronic medical illness, absence of major mental illness, negative pregnancy test and at least three months since last treatment at the clinic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Initial treatment of active methadone for at least 5 weeks. <BR/>15 weeks of stable dosing at 50, 20 or 0 mg per day<BR/>Gradual tapering for those receiveing active methadone from weeks 21-26<BR/>Individual counselling and group therapy (weekly).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Retention<BR/>Treatment compliance<BR/>Illicit drug use / Urinalysis (collected 3 x weekly, one sample selected at random for analysis for opioids, cocaine and benzodiazepines)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-03-26 10:20:45 +0100" MODIFIED_BY="[Empty name]">
<P>A subsample of 0mg patients (n=44) received an 8 week induction, reaching 0mg at 9 weeks. Data for patients in alternate 0mg treatment groups are collapsed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-24 01:12:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vanichseni-1991">
<CHAR_METHODS>
<P>Two group, open label, randomised clinical trial, with participants who applied for 45 day methadone detoxification and had at least six prior treatment episodes were randomly assigned to methadone maintenance or detoxification</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-24 01:12:56 +0100" MODIFIED_BY="[Empty name]">
<P>Geographic region: Thailand<BR/>Study setting: narcotics clinic<BR/>n = 240 males</P>
<P>30% unemployed, 52% unmarried<BR/>
</P>
<P>Eligibility criteria: heroin injectors applying for 45-day detoxification, at least 6 prior treatment episodes at the clinic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment: methadone maintenance (flexible dose, average 74mg) <BR/>Control: standard 45 day methadone detoxification</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Retention<BR/>Illicit drug use<BR/>Urinalysis (2 x week for opiates)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-01-24 01:19:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yancovitz-1991">
<CHAR_METHODS>
<P>Two group randomised clinical trial, with opioid dependent participants on waiting-lists for comprehensive methadone maintenance programs who were randomised to either the interim methadone program or wait list with frequent contact.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-01-24 01:19:11 +0100" MODIFIED_BY="[Empty name]">
<P>Geographic region: USA<BR/>Study setting: interim methadone clinic<BR/>n = 301, 79.4% male<BR/>55% Hispanic, 35% African American, 10% White<BR/>86% unemployed<BR/>Eligibilty criteria: wait list for comprehensive methadone maintenance program.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-03-26 10:21:06 +0100" MODIFIED_BY="[Empty name]">
<P>Control: wait-list with frequent contact<BR/>Treatment: "interim" methadone maintenance; standard physical exam on admission, flexible dosing 5 days a week, pick up on weekends from another site, minimal counselling, referral to community agencies</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-03-26 10:21:11 +0100" MODIFIED_BY="[Empty name]">
<P>Urinalysis (2 x weekly for heroin and cocaine)<BR/>Entry into conventional treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>For the first 3 months of the study there were three experimental groups; interim methadone, wait-list with frequent contact and bi-weekly urinalysis, and the wait-list with no contact. Recruitment slowed which resulted in the protocol being changed two experimental groups; interim methadone and wait-list with frequent contact. The wait-list then only lasted one month at which time the participants were switched to a methadone program.<BR/>Data from the initial discontinued minimal contact group is not include in the analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-01-17 03:09:07 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bale-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>The authors planned to conduct a randomised controlled trial comparing methadone maintenance, therapeutic communities and detoxification programs. Ethical and practical problems prevented random assignment and the study therefore does not meet inclusion criteria for this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-17 03:09:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dolan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-17 03:09:00 +0100" MODIFIED_BY="[Empty name]">
<P>This paper presents follow up results from the study reported in Dolan 2003.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-17 03:09:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwartz-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-17 03:09:07 +0100" MODIFIED_BY="[Empty name]">
<P>This paper presents follow up results from the study reported in Schwartz 2006.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-01-27 05:05:24 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-01-27 05:02:31 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-17 04:26:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolan-2003">
<DESCRIPTION>
<P>Drawing lots.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-26 22:10:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dole-1969">
<DESCRIPTION>
<P>Used release dates in a lottery.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 01:48:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gruber-2008">
<DESCRIPTION>
<P>"generated by a statistician".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-26 02:49:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gunne-1981">
<DESCRIPTION>
<P>"Randomly allocated"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 01:51:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinlock-2007">
<DESCRIPTION>
<P>Block randomisation procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-26 03:00:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newman-1979">
<DESCRIPTION>
<P>'Randomly assigned'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-26 03:02:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schwartz-2006">
<DESCRIPTION>
<P>'table of random numbers'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-26 03:07:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sees-2000">
<DESCRIPTION>
<P>'generated via computer software by statistician using various block sizes'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-26 03:10:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Strain-1993a">
<DESCRIPTION>
<P>'randomly assigned' stratified by race and sex. Unclear not enough information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 05:02:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vanichseni-1991">
<DESCRIPTION>
<P>Unclear. Not enough information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 01:57:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yancovitz-1991">
<DESCRIPTION>
<P>'randomly assigned'. Not enough information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-01-27 05:05:24 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-26 02:42:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolan-2003">
<DESCRIPTION>
<P>A-Adequate. Central allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-26 02:43:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dole-1969">
<DESCRIPTION>
<P>B- Unclear. Concealment of allocation not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-26 02:46:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gruber-2008">
<DESCRIPTION>
<P>B - Unclear. Individual sealed envelope not revealed to project staff. Does not state opaque.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gunne-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-26 02:53:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinlock-2007">
<DESCRIPTION>
<P>B- Unclear. Not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 05:01:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Newman-1979">
<DESCRIPTION>
<P>A - Adequate 'neither patients nor clinic staff knew which group' 'pharmacist only staff aware'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 05:05:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwartz-2006">
<DESCRIPTION>
<P>B - Unclear. Sealed envelope but unclear if opaque and sequentially numbered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 05:02:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sees-2000">
<DESCRIPTION>
<P>B - Unclear 'kept in sealed envelope'. Unclear if opaque and sequentially numbered.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Strain-1993a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 05:02:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vanichseni-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 05:02:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yancovitz-1991">
<DESCRIPTION>
<P>A - Adequate. 'assigned by administrative staff at another location'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-01-27 02:48:49 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-01-27 04:43:33 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.03 CMP-001.02">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-17 04:27:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolan-2003">
<DESCRIPTION>
<P>Missing outcome information balanced between groups. 191 randomised to each group, 124 and 129 followed up in each group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-26 02:44:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dole-1969">
<DESCRIPTION>
<P>No missing data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-26 02:49:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gruber-2008">
<DESCRIPTION>
<P>4 in detox group in MMT elsewhere</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-27 04:43:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gunne-1981">
<DESCRIPTION>
<P>No missing data. All controls refused drug free treatment and asked for discharge. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-26 03:01:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinlock-2007">
<DESCRIPTION>
<P>No missing data. Report ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-26 03:01:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Newman-1979">
<DESCRIPTION>
<P>No missing data. Report ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-26 03:04:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schwartz-2006">
<DESCRIPTION>
<P>Missing outcome information balanced between groups. 95% MMT and 89% wait list located for follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-27 01:55:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sees-2000">
<DESCRIPTION>
<P>Missing outcome information balanced between group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-26 03:10:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strain-1993a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-26 03:17:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanichseni-1991">
<DESCRIPTION>
<P>Urine provided for drop outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-27 01:58:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yancovitz-1991">
<DESCRIPTION>
<P>Missing outcome information balanced between group. Follow up 50% in MMT and 36% for control.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-01-27 02:48:49 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-01-27 04:43:49 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 02:04:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolan-2003">
<DESCRIPTION>
<P>Baseline characteristics similar.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 02:04:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dole-1969">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 04:43:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gruber-2008">
<DESCRIPTION>
<P>At baseline standard MMT group younger and detox group had more depressive symptoms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 04:43:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gunne-1981">
<DESCRIPTION>
<P>Only indiv 20-24. Baseline groups similar except gender - more women in MMT. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 02:06:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinlock-2007">
<DESCRIPTION>
<P>No differences between group at baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-26 03:02:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Newman-1979">
<DESCRIPTION>
<P>No difference between group at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 01:54:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schwartz-2006">
<DESCRIPTION>
<P>No difference between group at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 04:42:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sees-2000">
<DESCRIPTION>
<P>No differences between group at baseline. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 02:09:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strain-1993a">
<DESCRIPTION>
<P>Baseline groups similar.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-26 03:18:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vanichseni-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-27 01:59:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yancovitz-1991">
<DESCRIPTION>
<P>No baseline differences.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-03-16 10:17:51 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2009-03-16 10:17:51 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2009-03-16 10:17:47 +0100" MODIFIED_BY="Grade Profiler">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="7">
<TR>
<TD COLSPAN="7">
<P>
<B>Methadone maintenance treatment compared to No methadone maintenance treatment for opioid dependence</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B> Patient or population:</B> patients with opioid dependence</P>
<P>
<B> Settings:</B> Prisons, hospitals, community based treatments and research facilities</P>
<P>
<B> Intervention:</B> Methadone maintenance treatment</P>
<P>
<B>Comparison: </B>No methadone maintenance treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>No methadone maintenance treatment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Methadone maintenance treatment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Retention in treatment - Old studies (pre 2000)</B>
<BR/>objective</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 3.05 </B>
<BR/>(1.75 to 5.35)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>505<BR/>(3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>210 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>640 per 1000</B>
<BR/>(368 to 1123)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Retention in treatment - New studies</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 4.44 </B>
<BR/>(3.26 to 6.04)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>750<BR/>(4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>154 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>684 per 1000</B>
<BR/>(502 to 930)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Morphine positive urine or hair analysis</B>
<BR/>objective</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.66 </B>
<BR/>(0.56 to 0.78)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>1129<BR/>(6)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>701 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>463 per 1000</B>
<BR/>(393 to 547)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Criminal activity</B>
<BR/>objective</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.39 </B>
<BR/>(0.12 to 1.25)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>363<BR/>(3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>118 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>46 per 1000</B>
<BR/>(14 to 148)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Mortality</B>
<BR/>objective</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.48 </B>
<BR/>(0.1 to 2.39)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>576<BR/>(4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>17 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>8 per 1000</B>
<BR/>(2 to 41)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> RR 3.05</P>
<P>
<SUP>2</SUP> Other Cochrane review showing dose related effect : Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD002208. DOI: 10.1002/14651858.CD002208</P>
<P>
<SUP>3</SUP> RR 4.4</P>
<P>
<SUP>4</SUP> Too few numbers of events observed</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-03-16 09:22:03 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-03-16 09:22:03 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Methadone maintenance treatment vs No methadone maintenance treatment</NAME>
<DICH_OUTCOME CHI2="22.989476529708213" CI_END="5.673888369101471" CI_START="2.7069695115646324" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.9190614727481448" ESTIMABLE="YES" EVENTS_1="491" EVENTS_2="115" I2="73.90110213146227" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.753880787018495" LOG_CI_START="0.43248336436533175" LOG_EFFECT_SIZE="0.5931820756919133" METHOD="MH" MODIFIED="2009-02-10 04:54:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="8.000126947328434E-4" P_Q="0.0" P_Z="4.663767100901958E-13" Q="0.0" RANDOM="YES" SCALE="827.24" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.16342734233687753" TOTALS="SUB" TOTAL_1="687" TOTAL_2="568" WEIGHT="200.0" Z="7.234753129215361">
<NAME>Retention in treatment</NAME>
<GROUP_LABEL_1>Methadone MT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Methadone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.00544189139943" CI_END="5.34588662826272" CI_START="1.7456826490396686" DF="2.0" EFFECT_SIZE="3.054868496464522" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="63" I2="75.01699435044702" ID="CMP-001.01.01" LOG_CI_END="0.7280197443116541" LOG_CI_START="0.24196529532730465" LOG_EFFECT_SIZE="0.48499251981947933" MODIFIED="2009-02-10 04:54:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.01826592289404816" P_Z="9.177643313448028E-5" STUDIES="3" TAU2="0.174381980025924" TOTAL_1="254" TOTAL_2="251" WEIGHT="100.0" Z="3.911363731383583">
<NAME>Old studies (pre 2000)</NAME>
<DICH_DATA CI_END="17.71042113944224" CI_START="3.261356663696989" EFFECT_SIZE="7.6" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="5" LOG_CI_END="1.2482288884832011" LOG_CI_START="0.5133982960783813" LOG_EFFECT_SIZE="0.8808135922807914" MODIFIED="2009-01-17 06:05:37 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.43164312744868794" STUDY_ID="STD-Newman-1979" TOTAL_1="50" TOTAL_2="50" VAR="0.18631578947368424" WEIGHT="22.199087759487767"/>
<DICH_DATA CI_END="3.9899348566590613" CI_START="1.561180689545126" EFFECT_SIZE="2.495798319327731" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="17" LOG_CI_END="0.6009658050540523" LOG_CI_START="0.19345317079531085" LOG_EFFECT_SIZE="0.3972094879246816" MODIFIED="2009-02-10 04:48:45 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.2393749385836576" STUDY_ID="STD-Strain-1993a" TOTAL_1="84" TOTAL_2="81" VAR="0.057300361221929844" WEIGHT="35.17446315601359"/>
<DICH_DATA CI_END="2.9019957210021685" CI_START="1.6975333039408649" EFFECT_SIZE="2.2195121951219514" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="41" LOG_CI_END="0.46269676773420626" LOG_CI_START="0.22981830346851" LOG_EFFECT_SIZE="0.34625753560135814" ORDER="61" O_E="0.0" SE="0.13679396267665966" STUDY_ID="STD-Vanichseni-1991" TOTAL_1="120" TOTAL_2="120" VAR="0.018712588224783354" WEIGHT="42.62644908449865"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.8963464222541817" CI_END="6.037939347573477" CI_START="3.2599879749700515" DF="3.0" EFFECT_SIZE="4.436621424765478" ESTIMABLE="YES" EVENTS_1="318" EVENTS_2="52" I2="23.004792826804447" ID="CMP-001.01.02" LOG_CI_END="0.7808887461255597" LOG_CI_START="0.5132159981005209" LOG_EFFECT_SIZE="0.6470523721130403" MODIFIED="2009-02-10 04:52:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.27287662514922817" P_Z="2.6486396975065483E-21" STUDIES="4" TAU2="0.02357300521632304" TOTAL_1="433" TOTAL_2="317" WEIGHT="100.00000000000001" Z="9.475744952072127">
<NAME>New studies</NAME>
<DICH_DATA CI_END="16.01797933894697" CI_START="2.4224352235718394" EFFECT_SIZE="6.229166666666667" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="4" LOG_CI_END="1.2046077291455455" LOG_CI_START="0.3842521727521393" LOG_EFFECT_SIZE="0.7944299509488424" MODIFIED="2009-02-10 04:52:00 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.4818809146509831" STUDY_ID="STD-Gruber-2008" TOTAL_1="72" TOTAL_2="39" VAR="0.23220921590486807" WEIGHT="16.654045254872482"/>
<DICH_DATA CI_END="20.142264049407167" CI_START="3.5691762968696845" EFFECT_SIZE="8.47887323943662" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="5" LOG_CI_END="1.3041082849316674" LOG_CI_START="0.5525680001458311" LOG_EFFECT_SIZE="0.9283381425387492" MODIFIED="2009-02-10 04:52:08 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.44145848346760824" STUDY_ID="STD-Kinlock-2007" TOTAL_1="71" TOTAL_2="70" VAR="0.19488559262552055" WEIGHT="18.388811852777458"/>
<DICH_DATA CI_END="5.20728039372649" CI_START="2.5475296830874417" EFFECT_SIZE="3.642211055276382" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="25" LOG_CI_END="0.7166109635350317" LOG_CI_START="0.40611925298306817" LOG_EFFECT_SIZE="0.5613651082590501" MODIFIED="2009-02-10 04:52:36 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.18238436773697836" STUDY_ID="STD-Schwartz-2006" TOTAL_1="199" TOTAL_2="120" VAR="0.033264057594817355" WEIGHT="33.4989183448192"/>
<DICH_DATA CI_END="6.380757503929988" CI_START="2.7520385615865157" EFFECT_SIZE="4.190476190476191" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="18" LOG_CI_END="0.8048722398886086" LOG_CI_START="0.4396545149438903" LOG_EFFECT_SIZE="0.6222633774162494" MODIFIED="2009-02-10 04:52:24 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.21453069948942274" STUDY_ID="STD-Sees-2000" TOTAL_1="91" TOTAL_2="88" VAR="0.04602342102342101" WEIGHT="31.45822454753087"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.791555381621558" CI_END="0.7773465581375911" CI_START="0.5625837335744319" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6613036586608909" ESTIMABLE="YES" EVENTS_1="281" EVENTS_2="342" I2="53.667475881046805" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.10938532002549413" LOG_CI_START="-0.24981282908690933" LOG_EFFECT_SIZE="-0.1795990745562018" METHOD="MH" MODIFIED="2009-01-26 03:55:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.05567312633637045" P_Q="0.0" P_Z="5.348416597311513E-7" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.019842560975389858" TOTALS="YES" TOTAL_1="615" TOTAL_2="514" WEIGHT="100.00000000000001" Z="5.013372666646545">
<NAME>Morphine positive urine or hair analysis</NAME>
<GROUP_LABEL_1>MMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2077293208711022" CI_START="0.5967252159046765" EFFECT_SIZE="0.8489302325581395" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.08196961009276826" LOG_CI_START="-0.22422560972273248" LOG_EFFECT_SIZE="-0.07112799981498212" MODIFIED="2009-01-17 06:06:51 +0100" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.17986058781040795" STUDY_ID="STD-Dolan-2003" TOTAL_1="125" TOTAL_2="117" VAR="0.03234983104750547" WEIGHT="13.036841552068024"/>
<DICH_DATA CI_END="1.136342875763933" CI_START="0.595853498087739" EFFECT_SIZE="0.8228571428571428" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="14" LOG_CI_END="0.055509393509128466" LOG_CI_START="-0.224860506691218" LOG_EFFECT_SIZE="-0.08467555659104478" MODIFIED="2009-01-17 06:07:36 +0100" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.16469066723107254" STUDY_ID="STD-Gruber-2008" TOTAL_1="50" TOTAL_2="18" VAR="0.027123015873015868" WEIGHT="14.48771612498576"/>
<DICH_DATA CI_END="0.6663791821221947" CI_START="0.2830281717865378" EFFECT_SIZE="0.4342857142857143" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="40" LOG_CI_END="-0.17627857887419413" LOG_CI_START="-0.548170333936812" LOG_EFFECT_SIZE="-0.3622244564055031" MODIFIED="2009-01-24 03:44:47 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.21845105781765883" STUDY_ID="STD-Kinlock-2007" TOTAL_1="70" TOTAL_2="64" VAR="0.04772086466165412" WEIGHT="10.070891737804953"/>
<DICH_DATA CI_END="0.8413419776000589" CI_START="0.6062957269449949" EFFECT_SIZE="0.7142142857142857" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="80" LOG_CI_END="-0.07502744201834252" LOG_CI_START="-0.21731549257774854" LOG_EFFECT_SIZE="-0.14617146729804553" MODIFIED="2009-01-17 06:07:52 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.08358070523580478" STUDY_ID="STD-Schwartz-2006" TOTAL_1="175" TOTAL_2="101" VAR="0.006985734287714486" WEIGHT="25.362175954640684"/>
<DICH_DATA CI_END="0.7547952155685429" CI_START="0.5464040950365064" EFFECT_SIZE="0.6422018348623854" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="109" LOG_CI_END="-0.12217086136715699" LOG_CI_START="-0.26248605448557655" LOG_EFFECT_SIZE="-0.19232845792636677" ORDER="62" O_E="0.0" SE="0.08242183900916748" STUDY_ID="STD-Vanichseni-1991" TOTAL_1="120" TOTAL_2="120" VAR="0.006793359545653122" WEIGHT="25.545351229305375"/>
<DICH_DATA CI_END="0.7263255988974684" CI_START="0.33378832115457013" EFFECT_SIZE="0.49238095238095236" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="56" LOG_CI_END="-0.13886864912788321" LOG_CI_START="-0.476528862824108" LOG_EFFECT_SIZE="-0.3076987559759956" ORDER="63" O_E="0.0" SE="0.19834328097017695" STUDY_ID="STD-Yancovitz-1991" TOTAL_1="75" TOTAL_2="94" VAR="0.039340057106014556" WEIGHT="11.497023401195214"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="127" EVENTS_2="256" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-01-27 04:27:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="344" TOTAL_2="338" WEIGHT="0.0" Z="0.0">
<NAME>Self reported heroin use</NAME>
<GROUP_LABEL_1>Methadone MT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours methadone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5630138303488761" CI_START="0.3259394625660593" EFFECT_SIZE="0.4283788338388945" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="92" LOG_CI_END="-0.2494809366399053" LOG_CI_START="-0.4868630548857621" LOG_EFFECT_SIZE="-0.36817199576283366" MODIFIED="2009-01-27 03:03:30 +0100" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.13943943131805275" STUDY_ID="STD-Dolan-2003" TOTAL_1="129" TOTAL_2="124" VAR="0.019443355006301948" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6068955385849963" CI_START="0.06493157491163143" EFFECT_SIZE="0.19851116625310175" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.2168860550866284" LOG_CI_START="-1.1875440632117034" LOG_EFFECT_SIZE="-0.7022150591491658" ORDER="64" O_E="0.0" SE="0.5701693188073006" STUDY_ID="STD-Dole-1969" TOTAL_1="12" TOTAL_2="15" VAR="0.32509305210918116" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.6798858703848791" CI_START="0.8158963383646578" EFFECT_SIZE="1.170731707317073" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="15" LOG_CI_END="0.22527977723434145" LOG_CI_START="-0.08836501592263803" LOG_EFFECT_SIZE="0.06845738065585169" MODIFIED="2009-01-27 03:03:29 +0100" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.18423650406717537" STUDY_ID="STD-Gruber-2008" TOTAL_1="41" TOTAL_2="24" VAR="0.03394308943089432" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9252663375269533" CI_START="0.18763366186555316" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.033733237780905534" LOG_CI_START="-0.7266892456423064" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="65" O_E="0.0" SE="0.4070457892053471" STUDY_ID="STD-Gunne-1981" TOTAL_1="17" TOTAL_2="17" VAR="0.1656862745098039" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9292139721359" CI_START="0.4636977463115052" EFFECT_SIZE="0.6564102564102564" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="39" LOG_CI_END="-0.031884268549050764" LOG_CI_START="-0.3337650148802485" LOG_EFFECT_SIZE="-0.18282464171464963" MODIFIED="2009-01-27 03:03:28 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.17732624472874023" STUDY_ID="STD-Kinlock-2007" TOTAL_1="70" TOTAL_2="64" VAR="0.03144459706959707" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.45922729963177217" CI_START="0.2189716483023943" EFFECT_SIZE="0.31710843373493974" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="83" LOG_CI_END="-0.33797230238920706" LOG_CI_START="-0.659612112479105" LOG_EFFECT_SIZE="-0.49879220743415603" ORDER="66" O_E="0.0" SE="0.18893281658954378" STUDY_ID="STD-Yancovitz-1991" TOTAL_1="75" TOTAL_2="94" VAR="0.03569560918445819" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5358155683232786" CI_END="1.2495510137935848" CI_START="0.11945774358546075" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.38635287575312105" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" I2="21.12991082697581" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.09675399120020538" LOG_CI_START="-0.9227856928171257" LOG_EFFECT_SIZE="-0.41301585080846015" METHOD="MH" MODIFIED="2009-01-26 04:11:51 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.28141990442952836" P_Q="0.0" P_Z="0.11229446425403547" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2900316932825124" TOTALS="YES" TOTAL_1="178" TOTAL_2="185" WEIGHT="100.0" Z="1.5879640691160966">
<NAME>Criminal activity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours methadone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.716310836081461" CI_START="0.09927409656416836" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.14489847894777483" LOG_CI_START="-1.0031640565076627" LOG_EFFECT_SIZE="-0.5740312677277188" ORDER="67" O_E="0.0" SE="0.5041494487418058" STUDY_ID="STD-Dole-1969" TOTAL_1="12" TOTAL_2="16" VAR="0.25416666666666665" WEIGHT="65.90619588084957"/>
<DICH_DATA CI_END="3.87988750809627" CI_START="0.010309577253601012" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5888191340165585" LOG_CI_START="-1.9867591426885958" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="68" O_E="0.0" SE="1.5129074290546958" STUDY_ID="STD-Gunne-1981" TOTAL_1="17" TOTAL_2="17" VAR="2.288888888888889" WEIGHT="13.907385887257202"/>
<DICH_DATA CI_END="22.26195723886514" CI_START="0.18698694501195862" EFFECT_SIZE="2.040268456375839" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3475633442157438" LOG_CI_START="-0.7281887138227842" LOG_EFFECT_SIZE="0.30968731519647974" ORDER="69" O_E="0.0" SE="1.2193070340302339" STUDY_ID="STD-Yancovitz-1991" TOTAL_1="149" TOTAL_2="152" VAR="1.4867096432356057" WEIGHT="20.186418231893224"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.977298317224771" CI_END="2.39459726161265" CI_START="0.09814589994867004" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4847885139476743" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="24.571913879135373" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.3792324815222165" LOG_CI_START="-1.0081278383651524" LOG_EFFECT_SIZE="-0.3144476784214679" METHOD="MH" MODIFIED="2009-01-26 03:55:43 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.26392603257946723" P_Q="0.0" P_Z="0.3742941092711627" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.6573813292464701" TOTALS="YES" TOTAL_1="287" TOTAL_2="289" WEIGHT="100.0" Z="0.8884586302401153">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.916569884571867" CI_START="0.006441549098588444" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.28252465971381735" LOG_CI_START="-2.1910096785924673" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="70" O_E="0.0" SE="1.452966314513558" STUDY_ID="STD-Gunne-1981" TOTAL_1="17" TOTAL_2="17" VAR="2.1111111111111116" WEIGHT="23.98890364817263"/>
<DICH_DATA CI_END="7.934162244627808" CI_START="0.013617836577729414" EFFECT_SIZE="0.3287037037037037" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.899501077058996" LOG_CI_START="-1.865891881922707" LOG_EFFECT_SIZE="-0.4831954024318556" MODIFIED="2009-01-17 06:24:57 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="1.6244055130217714" STUDY_ID="STD-Kinlock-2007" TOTAL_1="71" TOTAL_2="70" VAR="2.638693270735524" WEIGHT="20.149149052268157"/>
<DICH_DATA CI_END="27.87074815972714" CI_START="0.32291921079481023" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.445148627029772" LOG_CI_START="-0.4909061175904472" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="71" O_E="0.0" SE="1.1372481406154653" STUDY_ID="STD-Newman-1979" TOTAL_1="50" TOTAL_2="50" VAR="1.2933333333333332" WEIGHT="34.04552171387362"/>
<DICH_DATA CI_END="4.213799325869655" CI_START="0.00987612289567472" EFFECT_SIZE="0.204" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6246738493208113" LOG_CI_START="-2.005413514469014" LOG_EFFECT_SIZE="-0.6903698325741012" ORDER="72" O_E="0.0" SE="1.544926336632564" STUDY_ID="STD-Yancovitz-1991" TOTAL_1="149" TOTAL_2="152" VAR="2.386797385620915" WEIGHT="21.816425585685604"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-01-27 05:05:25 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-01-27 05:05:25 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAAC1CAMAAAB8p+a8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAHf0lEQVR42u2d6ZKzKhCG/aZSxc3xL7fKzVE1Z+ZM4gKyyBKNRJ63
MmNENvulGzC0DAPoDf8GgRD6gv5CBt0BzuEcwDmAcwDnAM4BnIP2cOviLjVEW8/e+uD8JHN2Sqn/
hYN/se305wDOAZwDOAdwDq7KufS+JOK9BTJUoJQSbnfgXKpW5aj8qioF6fvZ9kmDJk36+z8pmpwD
x5BF0ZaIsfiPBNLkbKcMRprOrNL8WGADxc/hpBpFrMavyjasY6Aaw59/dsRY/OWCGtyUMhRpnaVa
FTOFK4jdRc8fopQBU6o2bGwoXG1cVxsJvVLVZlES3nfQc5keqEn/26OdqHT8jbBouXK7hYLXOVcr
KauIoKV7eTK6KmvwFQqLmRWp3j1F6M22PxVnNO5ypWdyCBy8y7H4a9ZkZFIoU9YkqzWByjHcH+1P
cz2abHNmHZ4jq1nsJmIwvm0QpBVxiEeaz0xpgxsL276FHfxYSsVbEn8n6jS/n/8uPOuG10xITHSz
ev4BYG2UtTZK3/q6XzDwuxqcAzgHcA6uAHwauhu349PQi1X8xrbTnwM4B3AO4BzAOYDzYVrCIqNL
WeRr65pk4ho+DSdwnuEAceBv4/g0nG7bpeezEPVEcBwXfF+HRYPHq358ycLIBN7xHM51W4h5Igxh
x4VVmHF5GH0e/PgKn4Zz9Nw4QLjmPLnmOeQjoWJXo+4VLIJ8v57LquFXRo6ZvhFQ/n7Oo/4G1Z4I
aiM5BJ9v2y0HiIA+ymILIdPJJa2gpTGc5c+Q8ETw/Bq8sDl5qABnzAgi6GStM7+ff4u9hQGw7a3h
p6ls4PwNwKfhIj0UgHMA5wDOQVdjOHwa8GnoED8Ig/4cwDmAcwDnAM7Bp3KevWQp5+Wbe+Ymi3LE
pyGBa87PWSlTwLkcFyIN8//xrczPZeTm66xNj8Dxxfp22CRwOa8/D2SzSqK2czMx1Fg/ZS4ED1Cd
hlhw//vcx8P8WcLu/uX1N2GHiUQ2dpJ7Mje78HugGKfQ+3I3C4av7jFYwnBaQGjLBMt5oFiJNn0Q
AsEb35RfgVCtlDHvYN/+PGsclz2+kyX5TjuErF4S7saG8gM4D7oTVWi/GXNFv0VSmw0govtAgKL5
eYbnQFwls5U1NBGTkTmaXKfe3hiCJlCq5yHXAuvCYJnU4JYMZreGYDahvRisJDJwyfJl8HZ+CLk8
YNvjKPNp+FRJsox/+MGnAT2/OlgbxT4NjNsBnAM4B3AOPhv4NHQ3bsenoRfg00B/DuAcwDmAcwDn
AM6TkDLtdCDXK2C23u0rQwXAbQwnzc/Tay9KlmeoUGJWyjRp259bKrj7L5iNHJwTZ0sGyxpY3koo
eLN6bvTR238hsJGDWm3a4O7VYO/4MB1Q8QY5l1EXh0wD7nozeLs7YNob7s/LnE4TvqvLiloob9W2
hzS2bvQ3e0AwePuQ+Xm9qjt+DuYc3hvWc8ftzHGBMK4TToA5dZ0jsO0psE9DJ8CnAdveQSuH6d44
x6ehuXE7gHMA5wDOAZwDOAdwDuAczjuAPjl9Wxmg5+g5gHNwPfCusF7Q27vCXm3Y+lXFaCADbDv9
OYBzwBgOXGlAe+vlRsdxnH78zx0PLWmex6KkZtwk6so24y6RXYPxkql1rNBOONfjnT8/2ZTP0hLT
WX7S1XShpmyTXA+5NdDOnUYLpT9Pze/qZ0la7NZYdy3t1h2VxUzoavq1+2CgvGyRXQORfcN9cS70
46Ozx62zaf87liYdlpSVZXv5VNUglKYzPRfD0tsVmviKpOLlsl+tQThNd/15icT0i5b59W5FvD5C
8NMwhsvoTOvnh3vNM3kmUz8/H8fBefdszY5Lk3oT/NoMREnlQ/PzQBrNc7j+zBe2vT/AOZwDOAdw
DuAcfB5ux039QVsQAc6ZqV97Wo5tpz8HcA7gHMA5uMZcbWPW1sqInoodxrmr/T+tVve7mYr9W5/+
YtsBnIOP4FyH+60xUGd0dF4crU2oTvWPxTVr4ElysGLav2X9Zollcy6e5YWGJpuLMbe8q0Q8mrjE
w3+9JSxxmsTKbbt+trb54ITPDVHPTVqvomo7pnYabyzjAhHPOYSqqt+v+sKpiKeveqqU1sYIHC+x
W8ENiNl5yvjAmZYbcqzSYn3FPhcmnXZc+Uanjbql3MvHy3EX97HKxriWgF1BvZLBeyT2VdJqRdIK
PRxlnn9OBBHtBEK2rpacsN0U502ZwwZXuN9F4NKBErtVWND5bkT+jYuMUUZxxrn96YljgypzdbTE
brXKVGAsp6gJTyttOdfvRLpYZfxBOFZiX5X6ozcattO4dfbYVlcpZWBGoXOmmCda94RwDpbYrdLu
GIMyMRy3MG7UdUyhl4vjFV3ccJ2i7RynqopzSfeEZdVUv19ilu+Sju609yNSo9JDhrqBUPd5ezO/
sbjP20Xufe0mvVRGy/U93iEkDiBdX3Vt3kpYesfZRIHE9njnwAH8XHc5pjjoLgvyCnPe7FaT361W
7PeDmt3to7SMiu0BfkvtD3AO5wDOAZwDOAefB3uuhjNyd5zjioxtB3AO4BzAOYBzAOcAzgEAb8L/
SqGVzPYrTf4AAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-01-27 05:05:25 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAO0AAAI0CAIAAAB+gTkWAAAU3klEQVR42u3dv47c1hXH8QXSpFCh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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-01-26 04:21:18 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2009-04-07 10:33:11 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-03-05 10:46:49 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-03-05 10:46:27 +0100" MODIFIED_BY="[Empty name]">Cochrane Central Register of Controlled Trials search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-03-05 10:46:49 +0100" MODIFIED_BY="[Empty name]">
<P>1. OPIOID-RELATED DISORDERS*:ME<BR/>2. ((*opioid or opiate) and (*abuse or dependen* or disorder*or addict*))<BR/>3. 1 or 2<BR/>4. Heroin<BR/>5. Opioid* or Opiate*<BR/>6. #3 or #4 or #5<BR/>7. METHADONE:ME or methadone<BR/>8. (placebo or withdraw* or detox* or untreated or "no treatment" or "drug free" or "wait list" or waiting)<BR/>9. #6 and #7<BR/>10. #9 and #8<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-04-07 10:33:11 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-03-05 10:47:14 +0100" MODIFIED_BY="[Empty name]">PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-04-07 10:33:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. "substance-related disorders" [MH]<BR/>2. "opioid related disorders" [MH]<BR/>3. ((*opioid OR opiate) AND (*abuse OR dependen* OR disorder* OR addict*))<BR/>4. 1 OR 2<BR/>5. Heroin [MH] OR heroin<BR/>6. Narcotics [MH]<BR/>7. opioid* OR opiate*<BR/>8. 5 OR 6 OR 7<BR/>9. 4 OR 8<BR/>10. methadone [MH] OR methadone<BR/>11. 9 AND 10<BR/>12. (placebo OR withdraw* OR detox* OR untreated OR "no treatment" OR "drug free" OR "wait list" OR waiting)<BR/>13. 11 AND 12<BR/>
<BR/>combined with the phases 1 &amp; 2 of the Cochrane Sensitive Search Strategy for the identification of RCTs as published in Appendix 5b2, Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>)<BR/>14. randomized controlled trial [PT]<BR/>15. randomized controlled trials [MH]<BR/>16. controlled clinical trial [PT]<BR/>17. random allocation [MH]<BR/>18. double blind method [MH]<BR/>19. single blind method [MH]<BR/>20. 14 OR 15 OR 16 OR 17 OR 18 OR 19<BR/>21. clinical trial [PT]<BR/>22. clinical trials [MH]<BR/>23. ((singl* OR doubl* OR trebl* OR tripl*) AND (blind* OR mask*))<BR/>24. PLACEBOS [MH] OR placebo*<BR/>25. random*<BR/>26. Research Design:ME<BR/>27. 14/26 OR<BR/>28. 13 AND 27<BR/>29. limit 28 to human<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-03-05 10:48:55 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-03-05 10:48:30 +0100" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-03-05 10:48:55 +0100" MODIFIED_BY="[Empty name]">
<P>1. drug abuse.me<BR/>2. Substance abuse.me<BR/>3. ((opioid or opiate) and (abuse$ or dependen$ or disorder$ or addict$))<BR/>4. 1 or 2 or 3<BR/>5. heroin.mp<BR/>6. Opiate.me or opiate$<BR/>7. opioid$<BR/>8. 5 or 6 or 7<BR/>9. 4 and 8<BR/>10. methadone.me or methadone<BR/>11. methadone treatment.me<BR/>12. 10 or 11<BR/>13. 9 and 12<BR/>14. (placebo or withdraw$ or untreated or "drug free" or detox$ or "wait list" or waiting)<BR/>15. 13 and 14<BR/>16. random$<BR/>17. placebo$<BR/>18. (singl$ or doubl$ or trebl$ or tripl$) and (blind$ or mask$))<BR/>19. crossover$<BR/>20. randomized controlled trial.me<BR/>21. phase-2-clinical-trial.me<BR/>22. phase-3-clinical-trial.me<BR/>23. double blind procedure.me<BR/>24. single blind procedure.me<BR/>25. crossover procedure.me<BR/>26. Latin square design.me<BR/>27. PLACEBOS.me<BR/>28. multicenter study.me<BR/>29. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28<BR/>30. 15 and 29<BR/>31. limit 30 to human</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-03-05 10:50:26 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-03-05 10:49:44 +0100" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-03-05 10:50:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. exp "Substance Use Disorders"/<BR/>2. ((drug or substance) and (addict* or dependen* or abuse* or disorder*))<BR/>3. 1 or 2<BR/>4. exp heroin/ or heroin<BR/>5. (opioid* or opiate*)<BR/>6. exp methadone/ or methadone<BR/>7. 3 or 4 or 5 or 6<BR/>8. (placebo or withdraw* or untreated or "drug free" or detox* or "wait list" or waiting)<BR/>9. 7 and 8<BR/>10. random*<BR/>11. (singl* or doubl* or tripl* or trebl*) and (mask* or blind*)<BR/>12. crossover*<BR/>13. allocate*<BR/>14. assign*<BR/>15. ((random*) and (allocate* or assign*))<BR/>16. exp Random Assignment/<BR/>17. exp Clinical Trials/<BR/>18. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17<BR/>19. 9 and 18</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>